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Abstract 
Introduction: Cancer is the second leading cause of death in the USA after heart diseases in both 
man and woman. Among all cancer types leukemia represents the leading cause of cancer death in 
man younger than 40 years. Single-target drug therapy has generally been highly ineffective in 
treating complex diseases such as cancer, endowed with the deregulation of multiple, redundant and 
aberrant signaling pathways. Based on the complexity that characterizes cancer, a growing interest 
has been directed toward multi-target drugs able to hit multiple targets. In the context of multi-
target strategy, plant products, based on their intrinsic complexity, could represent an interesting 
and promising approach. Aim of the research followed during my PhD was to indentify and study 
novel natural compounds for the treatment of acute leukemias. Two potential multi-target drugs 
were identified in Hemidesmus indicus and piperlongumine. 
Materials and Methods: The decoction of Hemidesmus indicus was characterized by HPLC to 
quantify its main phytomarkers. The study was conducted on different cell types. Induction of 
apoptosis, cell-cycle analysis, levels of specific proteins involved in the regulation of apoptosis, 
cell-cycle progression, angiogenesis and membrane differentiation markers were evaluated by flow 
cytometry. The mRNA levels of some proteins involved in the anti-leukemic activity of 
Hemidesmus were evaluated using TaqMan realtime PCR. The analysis of cell differentiation by 
nitroblue tetrazolium (NBT) reducing activity, adherence to the plastic substrate, α-napthyl acetate 
esterase activity and morphological analysis were performed through light microscopy (LM) and 
transmission electron microscopy (TEM). The effects of Hemidesmus on angiogenesis were studied 
in normoxic and hypoxic conditions through the use of an in vitro assay and LM. The capacity of 
Hemidesmus and piperlongumine to selectively kill leukemic stem cells (LSCs) was tested on the 
CD34+ cell fraction sorted from acute myeloid leukemia (AML) patient samples and on their 
healthy counterpart. 
Results: We have demonstrated that Hemidesmus modulates many components of intracellular 
signaling pathways involved in cell viability and proliferation and alters gene and protein 
expression, eventually leading to tumor cell death, mediated by a loss of mitochondrial 
transmembrane potential, inhibition of Mcl-1, increase in Bax/Bcl-2 ratio, and ROS formation. 
Hemidesmus induced a significant [Ca
2+
]i raise through the mobilization of intracellular Ca
2+
 stores 
and significantly enhanced the antitumor activity of three commonly used chemotherapeutic drugs 
(methotrexate, 6-thioguanine, cytarabine). Moreover, the decoction caused differentiation of HL-60 
cells as shown by NBT reducing activity, adherence to the plastic substrate, α-naphtyl acetate 
 esterase activity, and increasing expression of CD14 and CD15. The morphological analysis by LM 
and TEM clearly showed the presence of granulocytes and macrophages after Hemidesmus indicus 
treatment. Furthermore, we showed that Hemidesmus regulates angiogenesis of HUVECs in 
hypoxia and normoxia, by the inhibition of new vessel formation and the processes of 
migration/invasion. It is indeed able to inhibit key proteins and genes involved in neoangiogenesis 
such as HIF-1α, VEGF, and VEGFR-2. Clinically relevant observations are that its cytotoxic 
activity was also recorded in primary cells from AML patients. Moreover, both Hemidesmus and 
piperlongumine showed a selective action toward LSC. 
Conclusions: Our results identified the molecular basis of the anti-leukemic effects of Hemidesmus 
indicus and indentify the mitochondrial pathways, [Ca
2+
]i, cytodifferentiation and angiogenesis 
inhibition as crucial actors in its anticancer activity. The ability to hit selectively LSC exerted by 
Hemidesmus and piperlongumine enriched the knowledge of their anti-leukemic activity. On these 
bases, we conclude that Hemidesmus and piperlongumine can represent a valuable strategy in the 
anticancer pharmacology. 
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Chapter 1 
Introduction 
Cancer is the second leading cause of death in the USA after heart diseases in both man and 
woman. It is estimated that 1.6 million of new cases of cancer will be diagnosed in the United States 
in 2014, with a number of death estimated in 585,720. Among all cancer types, leukemia represents 
the leading cause of cancer death in man younger than 40 years. Moreover, it accounts for almost 
one-third of all cancers diagnosed in children aged 0 to 14 years. The amount of estimated death 
correlated to leukemia for 2014 in the USA is 24,090
1
. 
Leukemia is a cancer concerning the hematopoietic system and in particular blood and bone marrow 
(BM). It is characterized by an abnormal proliferation of immature white blood cells called “blasts”. 
Leukemias are classified either acute or chronic and, according to the type of blood cell affected, as 
either myelogenous or lymphocytic. Acute leukemia is characterized by a rapid proliferation of 
hematopoietic progenitor cells, which lose the ability to differentiate normally leading to an 
accumulation of cells at various stage of incomplete maturation and to a reduction in the production 
of healthy hematopoietic elements
2
. Chronic leukemia is characterized by a dysfunctional 
production of relatively mature, but abnormal, white blood cells. The progression of the pathology 
is slow and can takes months or years. The combination between these characteristics is used to 
define the four main categories of leukemia: acute myelogenous, acute lymphocytic, chronic 
myelogenous, and chronic lymphocytic leukemia
3
. 
It is not possible to indentify one single cause that leads to the development of leukemia, but most 
likely different leukemias have different causes. For most cases, the cause of leukemia is unknown. 
It is now clear that leukemia is a complex disease derived from multiple DNA mutations that lead to 
the activation of oncogenes or the deactivation of tumor suppressor genes. Many chemical 
substances such as solvents, alkylating chemotherapy agents, ionizing radiation or virus such as the 
human T-lymphotropic virus, represent, nowadays few known causes of leukemia’s development3. 
Leukemia is usually diagnosed trough the complete blood count and the examination after a 
complete evaluation of the patient’s clinical picture. A physical examination often reveals a swollen 
spleen and liver
3
. 
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1.1 Hematopoiesis 
Despite the complexity that characterizes the blood, it is probably the best understood human 
system. Blood is a highly regenerative tissue, with approximately one trillion (10
12
) cells arising 
daily in adult human BM from a hematopoietic stem cell (HSC). Nowadays, there are two models 
that describe the complexity of the blood organization: the classical model and the myeloid-based 
model
4
 (Fig. 1). 
 
The classical model of hematopoiesis 
The classical model classifies blood cells in two fundamental branches: lymphoid and myeloid. In 
the lymphoid category are included T, B, and natural killer cells, which carry out adaptive and 
innate immune responses. Otherwise, myeloid branch consists of a number of distinct, fully 
differentiated, short-lived cell types including granulocytes (neutrophils, eosinophils, mast cells, 
and basophils), monocytes, erythrocytes, and megakaryocytes. At the apex of hematopoietic 
hierarchy are placed the multipotent HSCs and their connection to mature cells is determined by a 
complex roadmap of specific lineage relationships between stem cells, progenitors, and mature 
cells
4
. 
The isolation of committed mouse progenitors of the myeloid (CMP) and lymphoid (CLP) lineages 
led to the formulation of the first comprehensive classical model of hematopoiesis
5-7
. The first 
principle of this model is that loss of self-renewal ability during differentiation precedes lineage 
commitment. This was deduced from the existence of multipotent progenitors (MPPs) that remain 
multipotent, but possess only transient repopulation ability
8, 9
. Another key postulate of the classical 
model is that the earliest commitment decision (downstream of MPPs) segregates lymphoid and 
myeloid lineages, inferred from the existence of CLPs and CMPs. Lastly, the classical model 
predicts that lineage decisions occur through several bifurcations. The first myelo-lymphoid split 
originates CMPs and CLPs and each of these undergo further commitment steps. CMPs give rise to 
granulocytic myeloid progenitors (GMPs), which become committed to the granulocyte-monocyte 
fate, and megakaryocytic/erythroid progenitors (MEPs), which only produce erythroid and 
megakaryocyte (E-MK) cells. On the lymphoid side, CLPs give rise to B cell precursors and the 
earliest thymic progenitors (ETPs) committed to the T and NK lineages. The classical model 
represents a simple yet powerful template for understanding hematopoiesis
4
. 
 
The myeloid-based model of hematopoiesis 
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The myeloid-based model of hematopoiesis postulates that the HSC first bifurcation is into a 
common myeloid–erythroid progenitor (CMEP) and a common myelo–lymphoid progenitor 
(CMLP); this model does not contemplate the presence of CLP
10-12
. CMLPs generate T and B cell 
progenitors through a bipotential myeloid–T progenitor and a myeloid–B progenitor stage, 
respectively. In this model, instead of splitting early in differentiation, lymphoid and myeloid fates 
remain coupled
13
. One postulate of this model is the existence of progenitors with myelo-lymphoid, 
but not E-MK, potential. This was confirmed with the isolation of lymphoid-primed multipotent 
progenitors (LMPPs) from adult mouse marrow
14
. A key principle of this model, supported by the 
balance of available evidence, is that lymphoid specification is not a single lineage bifurcation, but 
a gradual and possibly parallel process with many intermediate states. By contrast, myeloid 
development more closely adheres to the classical model
15, 16
. 
 
Figure 1: Current human hematopoiesis models. 
 
Stem cell concept 
Stem cells are highly undifferentiated cells characterized by self-renewal and differentiating 
capability. The regenerative potential is an essential property of stem cells that are present in 
different mammalian tissues
17
. Stem cells can generate either one or both daughter cells with the 
same stemness potential but uncommitted differentiation options (self-renewal division). On the 
other hand, they may generate progeny that exits the stem cell state to begin the stepwise process of 
differentiation into mature and specialized cells that usually lack in proliferative ability and intend 
to undergo in senescence (differentiation division). Regeneration requires conditions that favor self-
renewal divisions, whereas homeostasis requires that the outcomes of self-renewal and 
differentiation divisions are balanced. Stem cells constitute a reservoir of cells with active 
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mechanisms for self-renewal. For these reasons, stem cells obviously represent candidates for 
accruing the events that can generate a fully malignant cell population, and are the basis of the 
original concept of cancer stem cells (CSCs)
18
. 
 
Normal hematopoietic stem cells 
Hematopoiesis depend on the division of HSCs that are responsible for the formation of both new 
HSCs through self-renewal and differentiating progeny. Currently, non-obese diabetic/severe 
combined immunodeficiency (NOD/SCID) mice are used to assay human hematopoietic stem and 
progenitor cells
19
. Only those cells that are able to repopulate the hematopoietic system of these 
immunodeficient mice, as well as of secondary recipients, are thought to be HSCs. A common 
strategy adopted for the isolation of candidate repopulating cells consists first in the sorting of cell 
fractions according to the expression of some membrane antigens and then in the transplant of these 
sorted cells into NOD/SCID mice. According to several studies, the majority of normal HSCs are 
present among the CD34+/ CD38− cell fractions20, 21; some HSCs are also observed among 
CD34−/Lin− cells that possess a long-term repopulating ability22, 23; CD34+/CD38+ cell fractions 
contain some HSCs but endowed with short-term repopulating activity
24, 25
. 
According to their capability of repopulating hematopoiesis, the HSC pool can be subdivided into 
three groups: short-term HSCs, capable of generating clones of differentiating cells for only 4–6 
weeks; intermediate-term HSCs, capable of sustaining a differentiating cell progeny for 6–8 months 
before becoming extinct; and long-term HSCs, capable of maintaining hematopoiesis indefinitely
26
. 
The classical model and the myeloid-based model of hematopoietic hierarchy imply that all mature 
cells of the peripheral blood (PB) are the progeny of a single long-term HSC. Recent studies of stem 
cell purification, based on canonical HSC markers in combination with Hoechst dye efflux, 
provided evidence about the existence of myeloid-biased HSCs and lymphoid-biased HSCs, 
differentially responding to TGF-β1: the first ones are triggered to proliferate; the last ones are 
inhibited in their proliferation. These observations are compatible with the view that the 
hematopoietic system is maintained by a continuum of HSC subtypes rather than a functional 
uniform stem cell pool
27
. According to their differentiation stage, HSCs and progenitors are 
localized in specific tissue microdomains termed “niches”. These specific microenvironments play a 
crucial role in controlling HSC fate and regulate whether these cells remain quiescent, cycle to self-
renew and/or to differentiate, or undergo apoptosis. A particularly important role within the niche is 
exerted by some reticular cells responsible for the production of a chemokine, the stromal-derived 
factor 1 (fundamental for HSC homing), and a hematopoietic growth factor, the stem cell factor 
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(SCF) (essential for the survival of HSCs). Of note, stem cells present at the level of the BM niches 
possess not only the potentiality for hematopoietic differentiation but also an adipogenic and 
osteogenic differentiation potential. The maintenance of this adipogenic and osteogenic 
differentiation capacities is essential to maintain optimal microenvironmental conditions for HSC 
survival and maintenance in an undifferentiated state within the BM
28
. Within the HSC niche, the 
interaction between the receptors (i.e., cytokine receptors present on HSCs) and ligands (i.e., 
membrane-anchored receptors present on stromal cells) is essential for the maintenance of HSC 
survival, self-renewal, and differentiation and therefore essential for ensuring the homeostasis of the 
hematopoietic system. Studies carried out in recent years have led to the identification of some 
growth factors/cytokines that are essential for stem cell survival and/or self-renewal, such as SCF, 
thromboplastin, notch ligands, angiopoietin-1, angiopoietin-like proteins, and prostaglandin E2. In 
addition, recent studies have shown that pleiotrophin, a heparin-binding protein that is mitogenic for 
neurons, is a potent regulator for HSC expansion and regeneration both in mouse and man
29
. The 
ability of HSCs within the niche to self-renew and maintain multipotency depends on the balance of 
complex signals in their microenvironment. Among the various factors, low oxygen tension 
(hypoxia) plays a key role in maintaining undifferentiated states of HSCs
30
. Recent studies have in 
part clarified the role of hypoxia signaling at the level of the HSC compartment. The cellular 
responses to hypoxia are mediated by the hypoxia-inducible factors (HIFs) which regulate gene 
expression in a way that permits a cellular adaption to the hypoxic condition. It was shown that 
HIF-1α deficiency at the level of the HSC compartment causes an increased cell cycling rate and 
progressive loss of long-term repopulating activity
31
. Under steady-state conditions, the large 
majority of HSCs are quiescent, slowly cycling cell populations; however, in response to 
environmental cues, these cells are capable of intensive cycling activity, with dramatic expansion to 
ensure the proper homeostatic reconstitution of blood elements. The quiescence status of HSCs is 
considered as a very important protective mechanism, capable of reducing risks related to DNA 
replication and cellular oxidative metabolism
32
. HSCs possess an efficient cell-intrinsic mechanism 
to survive following exposure to DNA-damaging agents such as ionizing irradiation, characterized 
at the molecular level by the enhanced expression of pro-survival genes and strong p53 induction, 
which mediates, in turn, growth arrest and DNA repair; in contrast, the majority of myeloid-
committed progenitors undergo apoptosis following genotoxic exposure
33
. However, intriguingly, 
the HSC quiescence is a double-edged sword since, on one hand, it protects HSCs against potential 
endogenous stresses but, on the other hand, it renders HSCs intrinsically vulnerable to mutagenesis 
following DNA damage
33
. 
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1.2 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is a clonal disorder of HSCs characterized by the inhibition of 
differentiation and the subsequent accumulation of cells at various stages of incomplete maturation, 
and by reduced production of healthy hematopoietic elements. AML can occur in people of all ages, 
but is most common in older patients (older than 65 years). It can be caused by the exposure to 
ionizing radiations and drugs that damage DNA. Two types of chemotherapy-related AML exist. 
Drugs that target topoisomerase II, such as anthracyclines and epipodophyllotoxins, can cause 
patients to develop rapidly proliferative diseases, within 2 years of treatment
34
. More common is the 
so-called alkylator agent-induced disease occurring 5–6 years after exposure, characterized by a 
myelodysplastic prodrome with complex karyotypes and deletions in chromosomes 5 and 7
35
. In 
vitro and preclinical models have shown that the development of AML requires a multistep series of 
mutations. Leukemogenesis requires, at a least, activating mutations in class I genes that stimulate 
signal transduction pathways and induce cell to proliferate, in association with mutations in class II 
genes that affect transcription factors and compromise normal differentiation
36
. Mutations that lead 
to the activation of the receptor tyrosine kinase KIT, FLT3, and RAS signaling pathway belong to 
class I mutations. Examples of class II mutations are, RUNX1/ETO, CBFB/MYH11, and 
PML/RARα, which are fusion transcripts generated by recurring chromosomal abnormalities such as 
t(8;21), inv(16), and t(15;17), respectively
37
. 
AML is a biologically and clinically heterogeneous disease, characterized by distinct clinical 
presentations in different morphological and cytogenetic subtypes. Many mutations have been 
identified in patients with normal karyotypes (the majority of patients with AML) through 
molecular biology techniques (Tab. 1), and mutations in the NPM1
38
 and FLT3 genes are the most 
common and now routinely tested for. Although patients with NPM1 mutations have an improved 
outcome with chemotherapy alone, mutations in FLT3, which lead to constitutive receptor 
activation, dysregulation of FLT3 signal transduction pathways, and stimulation of cell 
proliferation, are associated with a worse prognosis, with a larger negative effect if the mutations 
are homozygous
39-42
. If these two mutations are present in combination, FLT3 mutations cancel out 
the better effects of NPM1 and the outcome becomes poorer than when NPM1 is mutated and FLT3 
is germline
43-45
. Several other mutations have been identified (Tab. 1); however, the prognostic 
effect of many of these findings is uncertain, with discrepant results reported by different groups. 
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Table 1: Molecular markers in AML. Copyright Ferrara and Schiffer 2013. 
 
Treatment of AML 
AML is conventionally treated in two steps: an induction phase followed by a consolidation, which 
includes stem cell transplantation (Tab. 2). The aim of induction is to achieve a complete remission 
(CR), whereas consolidation is designed to eliminate residual leukemia cells that persist after 
induction. CR is reached when in the BM there is less than 5% of leukemic blasts compared to a 
normocellular BM, absence of extramedullary leukemia, neutrophil count greater than 1,000/µL, 
and a platelet count greater than 100,000/µL
46
. 
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Table 2: Treatments of AML. Copyright Ferrara and Schiffer 2013. 
 
More than 30 years after its introduction
47
, the combination of an anthracycline, usually 
daunorubicin given for 3 days, with continuous infusion of cytarabine for 7 days (3+7) is still the 
standard induction regimen (Fig. 2). CR rates of patients treated with the 3+7 regimen are about 
70% in patients younger than 60 years. Numerous trials have been done to improve the rate and 
quality of CR, including the use of anthracyclines other than daunorubicin (eg, idarubicin 
hydrochloride and mitoxantrone)
48-50
, the addition of a third drug (usually etoposide), the use of 
high-dose instead of conventional dose of cytarabine
51
, the combination of anthracyclines with 
fludarabine phosphate 
52
 or cladribine
53
, and the use of hematopoietic growth factors such as 
granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor
54
. 
Overall, results have been disappointing, the alternative treatments tested for AML failed to show 
improvements in outcome. Many groups have shown that it is feasible to select specific induction 
treatment for patients according to molecular subtyping, which could become the standard for future 
clinical trials. So far, the only mutation that can be pharmacologically targeted is FLT3. Inhibitors 
such as midostaurin and lestaurtinib used in combination with the conventional chemotherapy are 
currently tested in newly diagnosed patients
55
. 
The achievement of CR regards only the first phase of treatment.Patients could eventually relapse
56
 
and thus consolidation treatment is essential (with the ultimate goal of cure) (Fig. 2). Number of 
cycles and optimum dose are not established, although three cycles of intermediate doses of 
cytarabine (1.5 g/m
2
) reduce toxicity without worsening treatment outcome
57, 58
, suggesting that this 
dose is reasonable for routine practice. Clinical trials and registry data strongly suggest that much 
lower relapse rates occur after allogeneic stem cell transplantation (stem cells obtained directly 
from the patient) than autologous stem cell transplantation (stem cells from a matched donor related 
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or unrelated with the patient) or chemotherapy, because of the graft-versus-leukemia effect. 
However, the main drawback that limits allogeneic stem cell transplantation is the significant 
treatment-related mortality of 10–25% because of graft-versus-host disease. Randomized trials have 
not shown a survival benefit from allogeneic stem cell transplantation compared with chemotherapy 
in the overall population of AML patients
59-61
. 
 
Figure 2: Practical approaches to management of AML. Copyright Ferrara and Schiffer 2013. 
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Acute promyelocytic leukemia 
Acute promyelocytic leukemia (APL) is a distinct subtype of AML with a unique morphology 
characterized by hypergranulated promyelocytes and the presence of a t(15;17) translocation that 
results in an abnormal fusion protein termed PML/RARα. It is clinically characterized by a severe 
hemorrhagic diathesis. As AML, APL is sensitive to anthracyclines, and studies reported that the 
association between anthracyclines and all-trans retinoic acid represents the best induction 
approach, able to achieve CR rates of over 90% and, with various consolidation approaches, cure 
rates of roughly 80%
62
. All-trans retinoic acid was the first, and perhaps the only, example of 
remission induction caused by the overcome of the inability of leukemic cells to differentiate into 
functional mature cells. Arsenic trioxide is perhaps now the most effective single agent drug
63
 and 
small trials without any chemotherapy, with combinations of all-trans retinoic acid and arsenic 
trioxide
64
 or arsenic trioxide alone
65
, have shown very promising results and are being assessed in 
large multicentre studies. The biggest challenge that remains now is to increase the diagnostic 
awareness about this highly curable disease, in order to reduce early mortality from hemorrhage by 
prompt initiation of all-trans retinoic acid treatment. 
 
Leukemic stem cells (LSCs) in acute leukemias 
The discovery that the large majority of AML blasts do not proliferate and only a minority of them 
(≈1%) is capable of forming colonies (colony-forming units, AML-CFU) when plated in a 
semisolid medium, brought to the discovery of LSCs in AMLs. Immunodeficient mice have been 
used to assay sorted fractions of AML cells. LSCs represent the leukemic counterpart of normal 
HSCs and are capable of inducing a leukemic graft when transplanted into immunodeficient mice. 
Initial studies have shown that the leukemia-initiating cells, as assayed in the NOD/SCID assay 
model, are detected only within the CD34+/CD38− fraction of the majority of AML samples66-69. 
However, some recent studies have shown that LSCs are present also in the CD34+/CD38+ 
fraction. In fact, it was shown that, in a significant proportion of AMLs, cells contained in the 
CD34+/CD38+ fraction are capable of initiating and maintaining the leukemic process when grafted 
in NOD/SCID mice
70
. These observations further reinforce the concept that the membrane 
phenotype of leukemia-initiating cells is heterogeneous in various AMLs. The extreme 
heterogeneity characteristic of leukemia cells in individual patients has many implications for the 
use and development of treatments that specifically affect the products of these gene mutations. The 
heterogeneity of LSCs limits the use of specific antibodies or drugs that target these progenitors
71
. 
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Another important factor that characterizes LSCs is their interactions with the BM 
microenvironment. Several key receptors and their ligands control the homing of leukemic stem 
cells to the microenvironment that plays a fundamental role in supporting AML LSC survival. 
These receptors and ligands such as VLA-4, CD44, CXCR4, IL-3Rα, CD47, represent crucial 
factors in the maintenance of the survival and self-renewing capability of LSC. Therefore, several 
promising pharmacological strategies were develop toward them (Tab. 3).  
 
Table 3: List of receptors and ligands that control the homing of LSC and pharmacological 
strategies. 
 
Concerning APL, many efforts, without success, have been made to grow APL cells in NOD/SCID 
mice. Anyway, a recent study proved that PML-RARα mediates the acquisition of a self-renewing 
capability in the promyelocyte compartment as an initiating step in the pathogenesis of APL
72
. 
Another study demonstrated that a sub-fraction of myeloid-committed cells isolated from PML-
RARα transgenic mice was capable of developing leukemia in recipient mice. According to these 
data, Guibal et al. suggested that myeloid-committed progenitors represent APL cancer-initiating 
cells
73
. 
  
Description Pharmacology strategy Reference
VLA-4
Control of AML bone marrow homing, 
sensitivity of leukemic blast to chemotherapy
Matsunaga T, 
Takemoto N, Sato 
T, Takimoto R, 
Tanaka I, Fujimi A, 
CD44 Homing and engraftment of AML stem cells
anti-CD44 mAb led to failed engraftment of 
leukemic cells
Jin L, Hope KJ, Zhai 
Q, Smadjia-Joffe F, 
Dick JE (2006) 
Targeting of CD44 
CXCR4
Homing, survival and response to 
chemotherapy  of AML stem cells. Elevated 
levels of CXCR4 are related with poor 
prognosis.
Rombouts EJ, 
Pavic B, 
Lowenberg B, 
Ploemacher RE 
(2004) Relation 
Interleukin-3 receptor alpha 
(IL-3Rα) CD123
Homing, survival of AML stem cells. 
Overexpressed in AML cells but not on HSCs
anti-CD123 inhibits the IL3 mediated survival 
of LSC in vitro and homing, engraftment, 
expansion and serial transplantation of AML 
in NOD/SCID mice. Less effects on HSC. A 
humanized version of anti-CD123 is in a 
phase I clinical trial.
Jordan CT, 
Upchurch D, 
Szilvassy SJ, 
Guzman ML, 
Howard DS, 
Pettigrew AL, 
Meyerrose T, 
CD47
Transmembrane ligand for the signal 
regulatory protein α (SIRPα) found on 
macrophage and dendritic cells. Their 
interaction results in an inhibitory effect on 
macrophage phagocytosis. Upregulated in AML 
LSC and it is associated with poor prognosis.
Inhibition of CD-47-SIRPα complex by a mAb 
induce an increase of AML LSCs phagocytosis, 
a reduction of engraftment and serial 
transplantation in NOD/SCID mice. No effects 
on HSC.
Majeti R, Chao 
MP, Alizadeh AA, 
Pang WW, Jaiswal 
S, Gibbs
KD, van Rooijen N, 
Weissman IL 
(2009) CD47 is an 
adverse 
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1.3 Acute lymphoblastic leukemia 
An estimated 6000 new cases of acute lymphoblastic leukemia (ALL) are diagnosed yearly in the 
USA. Patients are mainly children and roughly 60% of cases occur in people younger than 20 years. 
Survival in childhood ALL is approaching 90%
74, 75
. Established causes for childhood ALL are the 
exposure to ionizing radiation, as evidenced by the effects of the 1945 atomic bombs in Japan
76
, and 
the significantly increased risks associated with x-ray pelvimetry during pregnancy
77
. Anyhow, the 
first and most certain causal exposure for childhood ALL is infection. The illness is probably 
promoted indirectly by an abnormal or dysregulated immune response to one or more common 
infections (viral or bacterial) in susceptible individuals. Influenza viruses are plausible candidates
78
. 
Furthermore, the constitutive presence of trisomy 21 in infants represents an increased risk factor 
for the development of ALL (roughly 40 fold at age 0–4 years) and AML79. So far, common allelic 
variants in IKZF1, ARID5B, CEBPE, and CDKN2A have been significantly and consistently 
associated with childhood ALL
80-82
. The overall conclusion from these observations is that co-
inheritance of several low-risk variants affects the risk of ALL. The four genes represent key 
regulators of blood cell development, proliferation, and differentiation. Acquired or somatic 
mutations of each of these genes have been detected in ALL, suggesting that the inherited gene 
variants contribute to the intrinsic vulnerability of stem or precursor blood cells to transforming 
events either in uterus at initiation or with subsequent postnatal promotion and clonal evolution, or 
both
83
. It is possible to ascribe to these factors an incidence of ALL in 1 every 2,000 disease in 
childhood (0–15 years)84. Due to the rarity of the illness and the presence of different subtypes, the 
characterization of the epidemiology is complicated
85
. 
ALL is classified based on the phenotype of leukemic cells. Through molecular biology tests is 
possible to divide ALL into groups based on the immunophenotype of the leukemia, which takes 
into account the type of lymphocyte (B cell or T cell) the leukemia cells come from and how mature 
these leukemia cells are. Therefore, ALL is divided in B-cell disease that is subclassified in early 
pre-B ALL (pro-B ALL) (10% of cases), common ALL (50% of cases), pre-B ALL (10% of cases) 
and mature B-cell ALL (Burkitt leukemia) (4% of cases); and T-cell ALL that is sub-classified in 
pre-T ALL (5-10% of cases) and mature T-cell ALL (15-20% of cases)
86
. 
The pathobiology of ALL is extremely complex and characterized by several genetic alterations. In 
B lymphoblastic leukemia, these alterations include high hyperdiploidy with non-random gain of at 
least five chromosomes (including X, 4, 6, 10, 14, 17, 18, and 21); hypodiploidy with fewer than 44 
chromosomes; and recurring translocations including t(12;21)(p13;q22) encoding ETV6–RUNX1, 
t(1;19)(q23;p13) encoding TCF3–PBX1, t(9;22)(q34;q11) encoding BCR–ABL1, rearrangement of 
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MLL at 11q23 with a wide range of partner genes, and rearrangement of MYC into antigen receptor 
gene loci. The dysregulation of TAL1, TLX1, TLX3, and LYL1, particularly by rearrangement into T-
cell antigen receptor loci, often occurs in T lymphoblastic leukemia. These changes are of key 
importance in both pathogenesis and clinical management
83
 (Fig. 3).  
More than 50 recurring regions of DNA copy number alteration have been identified in ALL
87, 88
. 
The most common mutations are focal deletion and often implicate only one gene. The cell lineage 
and cytogenetic disease subtype influence the nature and frequency of these alterations. Notably, 
MLL-rearranged ALL, which is typically aggressive and arises early in life, harbors, on average, 
roughly one additional genetic alteration per case, whereas diseases associated with ETV6–RUNX1 
and BCR–ABL1 translocations manifest later in childhood and typically harbor between at least six 
and eight additional genetic alterations (Fig. 4A). Many of the implicated genes encode regulators 
of lymphoid development or cell cycle, tumor suppressors, or lymphoid signaling molecules
83
 (Fig. 
4B). 
 
Figure 3: Genetic pathogenesis of B lymphoblastic leukemia at diagnosis and relapse. Copyright 
Inaba and Mullighan 2013. 
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Figure 4: Cytogenetic and molecular genetic abnormalities in childhood ALL (A) and key genetic 
alterations in B lymphoblastic leukemia, by gene (B). Copyright Inaba and Mullighan 2013. 
 
The diagnosis of ALL is essentially done through the morphological identification of lymphoblasts 
by microscopy and immunophenotypic assessment of lineage commitment and developmental stage 
by flow cytometry
75
. 
Adolescents and adults have a lower incidence of favorable ALL (eg, ETV6–RUNX1, 
hyperdiploidy), greater prevalence of biologically high-risk subtypes (eg, BCR–ABL1, MLL 
rearrangement), and poorer adherence to, and tolerance of, treatment than do pre-adolescent 
children. The old age (≥60 years) and the high leukocyte count are poor prognostic factors in 
adults
89
. 
 
Treatment of ALL 
Treatment typically requires from 2 to 2.5 years, and is constituted by three phases: induction of 
remission, intensification (or consolidation), and continuation (or maintenance)
75
. The prevalence of 
drugs used in therapy was developed before 1970. However, doses and uses in combination 
chemotherapy have been optimized on the basis of leukemic-cell biological features, response to 
treatment, and pharmacodynamic and pharmacogenomic findings in patients, resulting in a high 
survival rate. Allogeneic HSC transplantation can be performed for patients at very high risk. 
The induction therapy takes 4–6 weeks in which the initial leukemic cell burden is eradicated and 
normal hematopoiesis is restored in 96–99% of children and 78–92% of adults with ALL74, 75, 90. 
Chemotherapy generally includes a glucocorticoid (prednisone or dexamethasone), vincristine, and 
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asparaginase, with or without anthracycline. Prednisone (or prednisolone) has traditionally been 
used, but dexamethasone is increasingly used
91
. The dose of dexamethasone is 7 times lower than 
that required forprednisone. Moreover, dexamethasone yielded better event-free survival, especially 
in children with T-cell disease who responded well to prednisone prephase treatment and children 
younger than 10 years with B-cell disease. The use of glucocorticoids is associated with infection, 
osteonecrosis, fracture, psychosis, and myopathy; these side effects appear generally more 
frequently with dexamethasone than with prednisone. Patients with BCR–ABL1-positive disease 
have poor prognosis but benefit from early treatment with tyrosine-kinase inhibitors (eg, imatinib, 
dasatinib). The association of tyrosine-kinase inhibitors with conventional chemotherapy conduces 
to CR in more than 90% of patients, with an event-free survival superior to historical results with 
chemotherapy alone
92
. 
The second phase of ALL treatment is represented by the consolidation therapy and its function is 
to eradicate residual leukemic cells
75, 90
. This goal is achieved with the use of high-dose (ie, 1–8 
g/m2) methotrexate with mercaptopurine, intensified by adding vincristine and glucocorticoids, 
uninterrupted asparaginase for 20–30 weeks, and reinduction therapy with drugs similar to those 
used during induction therapy. Intensified reinduction therapy with vincristine and asparaginase 
improved the outcome of patients with high-risk disease
93
. The main side effect associated with 
reinduction therapy is osteonecrosis, especially in children aged 10 years or older. Administration 
of dexamethasone in an alternating week schedule (10 mg/m2 per day on days 0–6 and 14–20) 
rather than continuous (10 mg/m2 per day on days 0–20) significantly reduced osteonecrosis despite 
delivering a higher cumulative dose
94
. 
Last step of ALL treatment is the so-called continuation therapy. It lasts 2 years or even longer and 
consists in the daily mercaptopurine and weekly methotrexate administration with or without pulses 
of vincristine and dexamethasone. Adherence of less than 95% to planned mercaptopurine doses is 
associated with relapse
95
. Therefore, uninterrupted, pharmacogenetics-based mercaptopurine dosing 
is important. In this phase an allogeneic HSC transplantation can be performed. It remains an option 
just for children with very high-risk or persistent disease
96
. 
 
LSCs in ALL 
The nature and the frequencies of stem cells in ALLs have been controversial. Several studies 
reported the identification of ALL LSC in different cellular sub-fractions. Hong et al. proposed that 
CD34+CD38
low
CD19+ leukemic blasts could represent a candidate for LSCs in ALL, due to their 
ability to re-initiate and sustain leukemic growth in immunodeficient NOD/SCID mice
97
. Recently, 
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Cox et al. have provided evidence that, in pediatric ALLs, there is a minority (i.e., <1%) of 
CD133+CD19− cells that are capable of initiating and maintaining long-term in vitro cultures of B-
ALL cells and of engrafting serial NOD/SCID recipient mice, with development of a B-ALL 
process
98
. Another study showed that sorted CD34+CD19−, CD34+ CD19+, and CD34−CD19+ 
populations all contain leukemia-initiating cells, although with different frequencies
99
. Importantly, 
it was proved that each fraction re-establishes the complete immunophenotype of the original 
leukemia and is able to self-renew: this observation demonstrates the ability of B-ALL blasts to 
move back and forth between the different populations
99
. As mentioned before, the Philadelphia 
chromosome t(9;22) leading to the BCR/ABL fusion oncogene and the translocation t(4;11) with 
formation of the MLL/AF4 fusion oncogene have been associated with a particular poor outcome. 
Cell fractionation studies have shown that both childhood high-risk ALL t(9;22) and t(4;11) 
originate in a primitive CD34+CD19− progenitor/stem cell population, without a myelo-erythroid 
differentiation potential
84
.  
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1.4 Limits of traditional anticancer therapy 
The traditional use of anticancer drugs is essentially based on their ability to act on cellular target 
involved in mechanisms of DNA duplication and repair. The ultimate goal of their activity is to 
inhibit the uncontrolled replication and induce the death of cancer cells (Fig. 5). Nevertheless, the 
major part of those drugs is not able to discriminate between healthy and cancer cells
100
. 
 
Figure 5: Main targets of traditional anticancer chemotherapy. 
 
Nowadays, several new anticancer approaches are based on the induction of cytotoxic effects on 
cancer cells targeting key factors of the programmed cell death process. This purpose is reached 
using agents able to selectively induce apoptosis in mutated cells
101
. 
Furthermore, most of the drugs used in clinic for the treatment of cancer, characterized by a 
mechanism of action that exploits the high proliferation of tumor cells, are toxic for cells in rapid 
proliferation (i.e. healthy cells in replicative state). For this reason, during anticancer treatment 
toxic events occur and bring to the induction of severe side effects like liver, kidneys or BM 
damages. Another frequent consequence, that can occur using chemotherapeutic agents with a wide 
range of action, is the development of secondary cancer sites, despite the treatment of the first 
cancer
101
. 
The low selectivity of many anticancer drugs is closely related to their low molecular weight. 
Indeed after intravenous administration, they distribute throughout most tissues of the body
102
. 
Drug resistance is one of the most critical problems that characterize anticancer therapy (Fig. 6). 
Some cancers (i.e. lung or colon) show an intrinsic drug resistance that appears since the first 
contact with chemotherapy agents. In this model of drug resistance both the stem cells and the 
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variably differentiated cells are inherently drug resistant, thus therapies have little or no effect, 
resulting in tumor growth (Fig. 6d). One of the main studied mechanisms of resistance is the efflux 
of drug from cancer cells. This event appears to be determined by several membrane proteins like 
ABC-transporter (ATP-binding-cassette). Within this family of proteins, the glycoprotein P (Pgp) is 
the best known. In most cases, the expression of Pgp is low, but high levels have been reported in 
kidneys, liver, pancreas, colon, small intestine and adrenals. The development of intrinsic resistance 
characteristic of adenocarcinomas in these tissues has been attributed to its high expression. 
Moreover, recent studies of imatinib resistance in patient with leukemias provide an example of 
how ABC-transporter-mediated efflux in stem cells could facilitate, but not be the solely 
responsible for, the acquisition of mechanisms of drug resistance
103-105
.  
An alternative model of drug resistance is the acquired one, where a tumor, originally sensible to 
drug treatment, becomes insensible to multiple anticancer drugs
106
. The acquisition of drug 
resistance can occur by a range of mechanisms, including the mutation or over-expression of the 
drug target, the inactivation of the drug, or the excretion of the drug from the cell. During anticancer 
treatment, cancer cells undergo an evolutionary pressure. This fact associated with a genomic 
instability brings to a selection of the most resistant cells to chemotherapy agents
106
 (Fig. 6a). 
Another fundamental mechanism for the acquisition of drug resistance has been attributed to the 
lost or alteration of the p53 gene. Functional alterations of p53 have been reported in most of 
cancers. These alterations can be originated by a gene mutation followed by its inactivation, or by 
an indirect inactivation through the binding with viral proteins or alterations of genes that interact 
and modulate p53. The inactivation of the p53 gene is essentially caused by small missense 
mutations or nucleotide insertions and deletions that led, in the 90% of cases, to the production of 
an aberrant protein. These mutations make the p53 protein unable to bind to the specific recognition 
sequences on the DNA, and bring to the miss transcription of target genes
107
. 
CSCs play a pivotal role in the mechanism of resistance. While chemotherapy kills most cells in a 
tumor, CSCs seem to be naturally resistant through their quiescence, their capability for DNA 
repair, and ABC transporter expression. As a result, LSCs that survive from anti-leukemic 
chemotherapy can support the regrowth and the relapse of the leukemia
7
 (Fig. 6b). 
In a forth model of resistance, the tumor stem cells, which express drug transporters, survive the 
therapy, whereas the committed but variably differentiated cells are killed. Those resistant stem 
cells originate a population of multidrug-resistant tumor cells that can be found in many patients 
who have recurrence of their cancer following chemotherapy (Fig. 6c). The same mechanisms that 
allow stem cells to accumulate mutations over time, producing the long-term consequences of 
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exposure to irradiation or carcinogens, would then allow CSCs to accumulate mutations that confer 
drug resistance to their abnormally developing offspring. As an example, genetic alterations such as 
those that up-regulate ABCB1 gene expression in human leukemia and lymphoma cells could have 
originated in the stem cell
108
. 
 
 
Figure 6: Models of tumor drug resistance. (a) In the conventional model of tumor-cell drug 
resistance, rare cells with genetic alterations that confer multidrug resistance form a drug resistant 
clone (yellow). Following chemotherapy, these cells survive and proliferate, forming a recurrent 
tumor that is composed of offspring of the drug-resistant clone. (b) In the cancer-stem cell model, 
drug resistance can be mediated by stem cells. In this model, tumors contain a small population of 
tumor stem cells (red) and their differentiated offspring, which are committed to a particular 
lineage (blue). Following chemotherapy, the committed cells are killed, but the stem cells, which 
express drug transporters, survive. These cells repopulate the tumor, resulting in a heterogeneous 
tumor composed of stem cells and committed but variably differentiated offspring. (c) In the 
“acquired resistance” stem-cell model, the tumor stem cells (red), which express drug transporters, 
survive the therapy, whereas the committed but variably differentiated cells are killed. Mutation(s) 
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in the surviving tumor stem cells (yellow) and their descendants (purple) can arise (by mechanisms 
such as point mutations, gene activation or gene amplification), conferring a drug-resistant 
phenotype. As in model a, the stem cell with the acquired mutations could be present in the 
population before therapy. (d) In the ‘intrinsic resistance’ model, both the stem cells (yellow) and 
the variably differentiated cells (purple) are inherently drug resistant, so therapies have little or no 
effect, resulting in tumor growth. Copyright Dean et al., 2005.  
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1.5 Multi-target and botanical drugs as a new anticancer strategy 
 
In the last years, the anticancer therapy strategy has been focused on the selective inhibition of key 
targets of cancer development. Even if chemotherapy brought a major contribution to the treatment 
of cancer, so far its results are not as good as prevented. One of the main causes of its partial failure 
is the development of resistance and relapse
100
. Most of the anticancer drugs used in therapy were 
designed to hit a single intracellular target. An example is cetuximab that binds an epidermal 
growth factor receptor, or infliximab that counteracts tumor necrosis factor. A target is a single 
gene, a gene product or a signaling pathway that has been identified based on genetic analyses or 
specific biological observations. In theory, a selective modulation of a single molecular mechanism 
should be sufficient to achieve a significant therapeutic effect with ideally less toxic effects than 
traditional treatments. However, single-target drug therapy has generally been highly ineffective in 
treating complex diseases such as cancer, endowed with the deregulation of multiple, redundant and 
aberrant signaling pathways. Any given cancer carries mutations in an estimated 300 genes and 
deregulation of more than 500 protein kinases
109
. The genetic plasticity and the advent of secondary 
mutations in cancer cells complicate the development of targeted therapy and may bring to the 
failure of targeted agents. Various cell signaling network models indicate that the partial inhibition 
of many targets is more effective than the complete inhibition of a single target
110
. 
Based on the complexity that characterizes a cancer, a growing interest has been directed toward 
multi-target drugs able to hit multiple targets. Aim of this strategy is to counteract the biological 
complexity of cancer with the association of more pharmacologically active agents
111
. In the context 
of multi-target strategy, plant products, based on their intrinsic complexity, could represent an 
interesting and promising approach. They are able to interact with numerous molecular targets, thus 
perturbing biological networks rather than individual targets
112
. They are also relatively safe and 
affordable in most cases. This evidence has been supported by the fact that the 70% of the 
anticancer drugs on the market are related to substances of natural origin. In recent years, the 
interest in further development of botanical drug products has been increasing steadily. 
Botanical drugs represent a complex mixture of constituents. Through their intrinsic complexity 
they are able to exhibit pharmacological effects by the interaction of many phytochemicals with 
multiple targets
113
. Multiple interactions may lead to a multi-target effect, which can results in the 
modification of transport across biological membranes, protection of an active compound from 
degradation, reversion of multidrug resistance mechanisms, activation of pro-drugs or deactivation 
of active compounds, and action of synergistic partners at different points of the same signaling or 
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different signaling pathways. However, the intrinsic complexity that characterizes botanical drugs 
can pose a number of problems, among which metabolic interactions with antineoplastic drugs and 
genotoxic potential are the most relevant
114
. 
Recently, the Food and Drug Administration (FDA) approved the first two botanical drugs for 
prescription use; Veregen
®
, a water extract of green tea leaves, for perianal and genital condyloma, 
and Fulyzq
™
, an extract of the red sap of the Croton lechleri plant, indicated for the symptomatic 
relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. Unlike 
most small molecule drugs that are comprised of a single chemical compound, the FDA approved 
drugs contain a mixture of known and possibly active compounds
115
. Of note, as specified in the 
FDA’s guidelines, the term botanicals does not include highly purified substances derived from 
botanical sources
116
. However, the approval of the first botanical drugs show that new therapies 
from natural complex mixtures can be developed to meet current FDA standards of quality control 
and clinical testing.  
Before marketing, botanical drugs should satisfy some legal requirements in order to prove their 
safety and efficacy as new drugs in reference to the Food, Drug & Cosmetic Act. Moreover, the 
procedure for the production has to guarantee the quality of the product. Essentially, the 
requirements for the quality, efficacy and safety of the product do not differ from the ones requested 
for any new drug approval. Concerning the quality of the product, it should be emphasized that 
natural products are usually constituted by complex mixtures where the active principle could be 
unknown. Anyhow, the main problem ascribable to botanical drugs is the therapeutic consistency of 
the different commercialized batches. Since the growing and the composition of the plant can be 
conditioned by culture methods, weather, seasonal changes and geographic location, the differences 
between batches can be a serius problem. Even if the quality control of botanical drugs is more 
complex than that for high purified drugs, a reasonable guarantees of quality shoud be made. Useful 
strategies include the control of raw material on field, chromatographic anlyses of commercial 
compounds and the development of biological assays relevant for the quantificaiton of their 
activity
115
. Of note, FDA determined that the therapeutic consistency of the commercial batches of 
simple botanical preparations (single part of single plant) can be assured. Although the chemical 
constituents of a botanical drug are not always well defined and in many cases the active constituent 
is not identified nor is its biological activity characterized
116
, variations in raw material quality can 
be minimized by restricting the cultivars and the composition of the preparation can be equivalent 
by robust chemistry, manufacturing and control measures, “fingerprinting”, conducting 
chromatographic analyses of marker compounds
115
. 
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In the last few years, interest in developing botanical drugs escalated. The number of submissions 
increased rapidly from 5–10 per year in 1990–1998 to an average of 22 per year in 1999–2002 and 
nearly 40 per year in 2003–2007115. Currently, in USA, there are about 10 to 20 botanical drugs that 
take place in clinical trials
117
. Among the therapeutic areas, the number of botanical products 
submitted to the FDA was particularly high for cancer and related conditions. Between 1982 and 
2007, more than 350 botanical investigational new drug (IND) applications and pre-IND 
consultation requests were submitted to the agency. These data indicate a growing interest in 
several therapeutic areas towards a rigorous clinical evaluation of botanical drugs, with a focus on 
indications where there is a clear medical need for new treatments
115
 (Fig. 7).  
 
Figure 7: Distribution of botanical drugs pre-INDs and IND submitted to FDA from 1999 and 
2007, categorized by therapeutic areas. Copyright Chen et al., 2008.  
 
Although, Veregen
®
 and Fulyzq
™
 are relatively simple botanical drugs, as they derive from a single 
part of a single plant, their commercialization prove the usefulness of FDA guidelines and 
guarantee the possibility to launch botanical drugs endowed with the same standards of highly 
purified drugs. 
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Hemidesmus var. indicus 
1.6 Hemidesmus Indicus 
 
 
 
 
 
 
Common name: Sarsaparilla indiana, Anantumul 
Scientific name: Hemidesmus Indicus R.Br 
Classification 
Family: Apocynacea 
Subfamily: Asclepiadoideae 
Type: Hemidesmus 
Species: Hemidesmus indicus /Hemidesmus pubescens 
Identification: is a common weed found all over India. 
Description: It is a perennial bush, woody, with thick and brown bark, that presents longitudinal 
grooves and transverse slits. It has numerous stems that become enlarged at the nodes. The leaves 
are opposite and petiolate, with different shapes, bright green with white streaks on the surface, 
gray-white on the underside, and smooth to the touch. The flowers present a tubular corolla and can 
be yellow or purple, based on the species. The fruits are two follicles, curved and sometimes apart. 
The seeds are flat, dark-gray with a white stripe. 
Uses: It is widely used in the Indian traditional medicine and has been extensively investigated for 
its pharmacological effects. It owns a variety of ethno-medicinal uses, the most important is 
probably the treatment of dysentery and diarrhea. It is also used for the treatment of infections, skin 
disease, menorrhagia, post-partum recovery, stomach ulcer and gastric ailments, fever, headache, 
pain and inflammation, sore mouth, venereal disease including gonorrhea and syphilis, impotence, 
as a blood purifier, cooling tonic, appetite stimulant, and to neutralize snake bite and scorpion 
sting
118
. The first pharmacological study was conducted in 1962 on the diuretic activity of the 
 
Hemidesmus indicus R. Br. 
 
Hemidesmus var. pubescens 
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root
119
, and since then, several studies have been published on Hemidesmus pharmacological 
properties
120-122
. 
 
Phytochemistry 
There are two variants of Hemidesmus in nature, indicus and pubescens. The roots are the part of 
the plant with the highest amount of active constituents. The components are similar between the 
two variants, although var. pubescens has been found to have a higher content of β-sitosterol and 
tannins whereas var. indicus has a higher content of phenols and free amino acids
121
. The major 
constituent found in the steam distillation product (yield, 0.25 %) is 2-hydroxy 4-methoxy benzoic 
acid (2H4MBAC, 91%), along with 40 minor constituents
123
. The aqueous extract of Hemidesmus 
root has been analyzed in order to quantitatively estimate its chemical constituents. The analysis 
reported the following constituents: saponins (12.55%), tannins (3.06%), flavonoids (1.12%), 
phenols (1.1%), alkaloids (1.23%), coumarins (0.91%), and terpenoids (0.79%)
124
. Several studies 
reported a wide variety of biologically active compounds in Hemidesmus roots (Tab. 4), including 
hemidesmins, a series of novel coumarino-lignans
125
, and steroidal glycosides known as 
hemidesmosides A-C
126
, which are thought to contribute to the therapeutic activity. 
 
Table 4: List of actives contained in Hemidesmus indicus. Copyright Das and Bisht, 2012. 
 
In vivo pharmacological studies 
Several beneficial effects has been reported in a wide range of in vivo animal studies of 
Hemidesmus root. Nowadays, there are no clinical trial reports available for Hemidesmus for any of 
its traditional uses, and many of the in vivo studies are of poor quality. However, from the sum of 
all the studies, a clear biological activity of Hemidesmus results and suggests that this plant has a 
high potential for therapeutic use in some of its traditional indications. Some of the beneficial 
26 
 
effects include cancer chemoprevention and antitumour activity, hepatoprotection, free radical 
scavenging and antioxidant activity, cardioprotection, neuroprotection, antithrombotic and 
hypolipidaemic effects, renal protection, antiulcer activity, anti-infective and anti-inflammatory 
activity
127
 (Tab. 5). 
 
Table 5: Summary of in vivo animal studies on Hemidesmus indicus root. Copyright Das and Bisht, 
2012. 
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In vitro pharmacological studies 
Most in vitro studies support the evidences reported by in vivo studies
127
 (Tab. 6). In particular, the 
anti-inflammatory and antioxidant activities of Hemidesmus were confirmed. The antimicrobic 
activity has been extensively studied in vitro and several mechanisms of action have been suggested 
to be related with the traditional use of Hemidesmus as antidiarrheal
128, 129
. 
 
Table 6: Summary of in vitro/in vivo studies on Hemidesmus indicus root. Copyright Das and Bisht, 
2012. 
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Safety and toxicity of Hemidesmus indicus 
The toxicity of the plant for the liver and the kidney has been reviewed by Austin et al.
121
. The 
samples of Hemidesmus collected during the vegetative season presented a lower concentration of 
active constituents and higher value of the lethal dose 50 (DL50) compared to the once collected in 
the blossoming season. The DL50 of the 50% alcoholic extract of the Hemidesmus root was 915,21 
mg/kg b.w. in the vegetative season and 853,17 mg/kg b.w. in the blossoming season. The powder 
suspension of the root has been tested for its acute toxicity in albino Swiss mice. None death or 
behavioral alteration has been observed up to 5g/kg b.w.
130
 and 12 g/kg b.w.
131
. Das and colleagues 
showed that Hemidesmus 600 and 800 µg/mL was able to reduce the vitality of embryonic 
interstitial cells and lymphoid cells by 50% (CD50), respectively. The CD50 of the chloroformic 
fraction was 500 µg/mL in both cell lines
118, 127-129
. Among the most important therapeutic 
indications of Hemidesmus, there are diarrhea and dysentery, but for these uses the method for the 
preparation of the root is crucial. The alcoholic extract inhibits the absorption of water and 
electrolytes from the intestine, and this would be a risk for patients affected by diarrhea and 
dysentery, while the water extract has the opposite effect, stimulating the absorption of water and 
electrolytes
131
. This indicates that the plant contains one or more components that are toxic in 
defined conditions
127
. 
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1.7 Piperlongumine 
 
Piperlongumine (piperlongumine, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-
propenyl]-2(1H)-pyridinone) is a biologically active component derived from Piper species 
(Piperaceae). Interestingly, piper seeds are used in traditional medicine, including the Indian 
Ayurvedic system of medicine and the folk medicine of Latin America. In particular, 
piperlongumine is the principal alkaloid from long pepper (Piper longum L.)
132
. P. longum root is 
traditionally used to induce expulsion of the placenta after birth, or for treatment of tumors, diseases 
of the spleen, malaria, viral hepatitis, bronchitis, cough, asthma, respiratory infections, 
stomachache, and gonorrhea
133
. The main pharmacological activities reported for piperlongumine 
include cytotoxic
132, 134-143
, anti-angiogenic
142
, antimetastatic
142
, antiplatelet aggregation
143-148
, anti-
atherosclerotic
149
, antidiabetic
150
, antifungal
151
, and schistosomicidal
152, 153
 activities. 
 
Chemical structure of piperlongumine 
Piperlongumine was isolated and characterized as a new amide alkaloid for the first time in 1961 by 
Atal and Banga, a pair of Indian chemists working with P. longum (Fig. 8.1). After several reports 
from different groups, in 1968 Kamat and Saksena published the correct structure of 
piperlongumine. Further studies in the 1980s allowed comparison of the X-ray crystallographic data 
of piperlongumine obtained from an improved synthetic route, and of piperlongumine isolated from 
P. longum, definitively establishing the accuracy of structure
132
 (Fig . 8.2). 
 
Figure 8: Proposed chemical structure (1). Correct structure of piperlongumine (2) (5,6-dihydro-1-
[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)- pyridinone). Copyright Bezerra et al, 
2012. 
 
Biological effects of piperlongumine 
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Piperlongumine shows multiple in vitro and in vivo pharmacological activities (Tab. 7). These 
activities include antiplatelet aggregation, anxiolytic, antidepressant, antinociceptive, anti-
atherosclerotic, antidiabetic, antibacterial, antifungal, leishmanicidal, trypanocidal, and 
schistosomicidal properties
131-152
.
 
 
Table 7: Summary of the reported pharmacological effects of piperlongumine. Copyright Bezerra et 
al., 2012. 
 
Anticancer effects of piperlongumine 
Beyond the several pharmacological activities attributed to piperlongumine, different research 
groups have extensively investigated its anticancer potential. Therefore, a patent that provides 
methods for the treatment of cancer using piperlongumine and/or its analogs has been published
154
. 
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Cytotoxicity studies 
Several studies concerning the cytotoxic activity of piperlongumine against tumor cell lines have 
been performed (Tab. 8). Piperlongumine is able to kill several types of cancer cells, including 
hematological, colon, melanocyte, lung, breast, central nervous system (CNS), pancreatic, 
nasopharyngeal, osseous, bladder, renal, and prostate cells. The IC50 values reported in the different 
cancer cell lines were in the micromolar range. This compound showed a selectivity of action 
against cancer cells and presented only a weak activity in normal cells 
132, 134-143
. 
A common strategy to reduce chemoresistance is the use of drugs in combination. Interestingly, 
piperlongumine increased the cytotoxicity of 5-fluorouracil (5-FU) in several cell lines, as observed 
by the lower IC50 value and increase in the maximum response achieved
155
. As well, the association 
of piperlongumine with diferuloylmethane (curcumin), an anti-inflammatory and anticancer agent, 
enhanced piperlongumine induced cytotoxicity
140
. 
 
Table 8: In vitro cytotoxic effects of piperlongumine against normal and tumor cell lines. Copyright 
Bezerra et al., 2012. 
Cytotoxic mechanisms 
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Understanding the molecular mechanism of drugs is vital for predicting their potential therapeutic 
and side effects. For this purpose, several studies investigated the molecular and cellular mechanism 
by which piperlongumine induces cytotoxicity (Fig. 9). Bezerra et al. in 2007 studied the activity of 
piperlongumine on human leukemia cells (HL-60 and K-562). Piperlongumine showed the ability to 
suppress leukemia growth and reduce cell survival, triggering cell death by both caspase-dependent 
apoptosis and/or necrosis. However, only a weak cytotoxicity was observed in normal lymphocytes. 
Later studies, by the same group, reported the effects of piperlongumine in the inhibition of cell-
cycle progression in G2/M phase followed by mitochondrial dependent apoptosis
156
. This result was 
confirmed in other cell lines. In particular, in PC-3 cells (androgenin-dependent prostate 
carcinoma), the G2/M arrest was associate with a dose-dependent decrease in CDK-2 expression
157
. 
The pro-apoptotic activity exerted by piperlongumine was mainly correlated to a down-regulation 
of Bcl-2 and to the activation of caspase-3. Piperlongumine effects on cell death, cell cycle and 
signal transduction pathways were also evaluated in a mouse embryonal carcinoma cell line 
(PCC4). In contrast to previous works, piperlongumine induced a significant increase of cells in the 
G1 phase of the cell cycle. A decrease in CDK2 and cyclin D1 (two G1 cell-cycle regulators) was 
found
140
. Additionally, piperlongumine showed the ability to inhibit HIF-2 transcription activities in 
a renal carcinoma cell line (786-0)
137
. Raj et al. in 2011 demonstrated that piperlongumine exerted 
its cytotoxic activity toward cancer cells through the induction of p53 expression and acetylation. 
Additionally, piperlongumine showed the ability to repress the expression of several pro-survival 
proteins, including Bcl-2, survivin, and Xiap. Moreover, Raj et al. reported that piperlongumine was 
able to up-regulate members of the pro-apoptotic BH3 only family, like Bim, Puma and Noxa
142
. A 
crucial role for piperlongumine’s induction of apoptosis was attributed to its ability to stimulate the 
production of reactive oxygen species (ROS), like hydrogen peroxide and nitric oxide, in cancer 
cells. Moreover, the combination of piperlongumine with N-acetyl-L-cysteine (NAC), an 
antioxidant agent, prevented ROS production and cell death. In contrast, the induction of ROS was 
not reported in normal cells
142
. 
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Figure 9: Summary of the anticancer mechanisms of piperlongumine. Copyright Bezerra et al. 
2012. 
 
Toxicological profile of piperlongumine 
Several toxicology studies on piperlongumine are found in literature. As genotoxic compounds are 
potentially mutagenic or carcinogenic, the genotoxic potential of piperlongumine has been 
investigated in many models. Piperlongumine induced DNA strand breaks in V79 cells (Chinese 
hamster fibroblast cell line)
155
.Subsequent studies in the same cell line reported that piperlongumine 
is able to induce significant chromatid and chromosomal aberrations, and to increase the incidence 
of micronuclei
158
. In mouse BM micronucleus assay, piperlongumine at 50 mg/kg b.w. does not 
induce micronucleus formation, but at 100 mg/kg it increased the levels of micronucleated 
immature polychromatic erythrocytes. Hematological, biochemical, histopathological and 
morphological analyses of the piperlongumine-treated animals were also performed on healthy 
Swiss mice after 7 days of treatment at a dose of 50 mg/kg. Neither the enzymatic activity of 
transaminases nor the urea levels were significantly modified when compared with the control 
group; hematological parameters also remained unchanged
156
. 
  
34 
 
Chapter 2 
Research aim 
My research project aims to indentify and study novel natural compounds for the treatment of acute 
leukemias. Single-target drug therapy has generally been highly ineffective in treating complex 
diseases such as cancer, characterized by the deregulation of multiple, redundant and aberrant 
signaling pathways. On these bases, a growing interest has been directed toward multi-target drugs 
able to hit multiple targets. Aim of this strategy is to counteract the biological complexity of cancer 
with the association of more pharmacologically active agents
111
. In the context of multi-target 
strategy, plant products, based on their intrinsic complexity, could represent an interesting and 
promising approach. They are able to interact with numerous molecular targets, thus perturbing 
biological networks rather than individual targets
112
. Two potential multi-target drugs were 
identified in Hemidesmus indicus and in piperlongumine. In the first two years of my PhD I 
investigated the multi-target activity of Hemidesmus indicus decoction; in the last year, I explored 
the ability of piperlongumine of selectively hitting LSC. 
From preliminary studies conducted in our lab, Hemidesmus showed the ability to induce cytostatic 
and cytotoxic effects on a T-lymphoblastoid cell line. Starting from these results the cellular and 
molecular mechanisms by which Hemidesmus exerts its anti-leukemic activity were investigated. 
The first part of the research was conducted on Jurkat cells examining the effect of Hemidesmus in 
the modulation of key factors involved in the regulation of apoptosis and cell-cycle. We thus 
evaluated the ability of Hemidesmus to induce apoptosis, regulate the activation of caspase-3, and 
the cleave one of its essential substrates, PARP. Afterwards, it was investigated whether the pro-
apoptotic effect of Hemidesmus was induced through the extrinsic or the intrinsic pathway. To this 
purpose, the modulation of caspase-8 activity and of the mitochondrial transmembrane potential 
were studied. Therefore, the ability of Hemidesmus to mobilize intracellular levels of Ca
2+
 was 
investigated. The research continued analyzing the ability of Hemidesmus to induce a post-
transcriptional and post-translational modulation of proteins involved in the regulation of the 
intrinsic apoptotic pathway, such as Bax, Bcl-2, Mcl-1, and Noxa. Moreover, the ability of 
Hemidesmus to modulate the 26S proteasome and level of ROS was investigated. In parallel, the 
expression of proteins involved in the inhibition of cell-cycle progression by Hemidesmus was 
examined. 
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In the second part of the study, it was investigated the ability of Hemidesmus to induce 
differentiation in a human promyelocytic leukemia cell line and its ability to influence new blood 
vessels formation. 
In the third and final part of the research, a preliminarily exploration of the ability of Hemidesmus 
to induce apoptosis in primary AML cells in culture was performed. Furthermore, due the pivotal 
role in the process of leukemia initiation and progression of LSCs, the ability of Hemidesmus and 
piperlongumine to selectively target those cells, sorted from AML patient and healthy cord blood 
samples, was evaluated. 
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Chapter 3 
Materials and methods 
 
Plant decoction preparation 
Hemidesmus indicus (voucher #MAPL/20/178) was collected from Ram Bagh (Rajasthan, India), 
and authenticated by Dr. MR Uniyal, Maharishi Ayurveda Product Ltd., Noida, India. The method 
described in the Ayurvedic Pharmacopoeia of India
159
 was followed for the preparation of 
Hemidesmus. In particular, 10 g of grinded roots were mixed with 300 mL of boiling water, 
allowing the volume of water to reach 75 mL. The yield of the decoction was 15%. Hemidesmus 
was then filtered, lyophilized, and stored at room temperature. Immediately before the use, the 
samples were resuspended in water and centrifuged at 2,000 rpm to discard any insoluble material. 
 
HPLC analysis of plant decoction  
Hemidesmus was subjected to HPLC analysis to quantify its main phytomarkers, namely 2-
hydroxy-4-methoxybenzaldehyde (2H4MBAL), 3-hydroxy-4-methoxybenzaldehyde (3H4MBAL) 
and 2H4MBAC
127
. The reference compounds (all obtained from Sigma, St. Louis, MO, USA) were 
used as external standards to set up and calculate appropriate calibration curves. The analyses were 
performed using a Jasco modular HPLC (Tokyo, Japan, model PU 2089) coupled to a diode array 
apparatus (MD 2010 Plus) linked to an injection valve with a 20 mL sampler loop. The column 
used was a Tracer Extrasil ODS2 (2560.46 cm, i.d., 5 mm) with a flow rate of 1.0 mL/min. The 
mobile phase consisted of solvent solution B (methanol) and A (water/formic acid=95:5). The 
gradient system adopted was characterized by five steps: 1, isocratic, B/30 for 15 min; 2, B raised 
progressively from 30% to 40% at 20 min; 3, B then raised to 60% at 50 min; 4, B achieved 80% at 
55 min and 5, 100% at 60 min. Injection volume was 40.0 mL. Following chromatogram recording, 
peaks from Hemidesmus samples were identified by comparing their UV spectra and retention time 
with those from the pure standards. The identity was also confirmed by 
1
H NMR on the enriched 
fraction of the compounds obtained by soxhlet extraction in CHCl3/EtOH 1:1. Dedicated Borwin 
software (Borwin ver. 1.22, JMBS Developments, Grenoble, France) was used to calculate peak 
area by integration. 
 
Standard solution and calibration procedure  
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Individual stock solutions of 2H4MBAL, 3H4MBAL and 2H4MBAC were prepared in water. Six 
different calibration levels were prepared within the following range: 2–20 mg/mL for 2H4MBAL, 
1.5–40.0 mg/mL for 3H4MBAL, and 1–100 mg/mL for 2H4MBAC. Each calibration solution was 
injected into HPLC in triplicate. The calibration graphs were provided by the regression analysis of 
peak area of the analytes versus the related concentrations. The analysis of Hemidesmus (31 
mg/mL) was performed under the same experimental conditions. The obtained calibration graphs 
allowed the determination of the concentration of the three components. Three different batches of 
Hemidesmus indicus were tested. 
 
Cell cultures 
Human leukemia Jurkat (acute T lymphoblastic leukemia), CEM (acute T lymphoblastic leukemia), 
HL-60 (acute promyelocytic leukemia), REH (non-T, non-B lymphoblastic leukemia) and KU812F 
(chronic myeloblastic leukemia) cell lines, obtained from the Istituto Zooprofilattico of Brescia 
(Italy), were grown in suspension and propagated in RPMI 1640 supplemented with 10% (Jurkat, 
CEM, REH, KU812F) or 20% (HL-60) heat inactivated bovine serum, 1% antibiotics (all obtained 
from Sigma St. Louis, MO, USA). To maintain exponential growth, the cultures were divided every 
third day by dilution to a final concentration of 1x10
5
 cells/mL. To reduce spontaneous 
differentiation of HL-60, cells were never allowed to exceed a density of 1.0x10
6
 cells/mL. 
Human umbilical vein endothelial cells (HUVECs) were purchased from Lonza (Basel, 
Switzerland), cultured in EGM complete medium with SingleQuots™ (supplements and growth 
factors containing hydrocortisone, hEGF, FBS, VEGF, hFGF-B, R3-IGF-1, ascorbic acid, heparin 
and gentamycin/amphotericin-B, Lonza) at 37°C and 5% CO2 under normoxic (21% O2) and 
hypoxic (2.5% O2) conditions. To maintain the exponential growth, the cells were divided when 
they reached the 80% of confluence in a 25 cm
2
 dish. HUVECs at passage between 3 and 8 were 
used for the experiments under normoxic and hypoxic conditions. 
Cells were treated with different concentrations of Hemidesmus within the following range: 0.0-3.1 
mg/mL. The stock solution (31 mg/mL) was diluted to 1/10 and the concentration 3.1 mg/mL was 
obtained. A series of two-fold dilution was used to obtain the lower concentrations. 
 
Patients 
The characteristics of the patients studied are given in Table 9. The diagnosis of leukemia was 
established by combination of morphological, immunological, cytogenetic and molecular methods, 
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which were applied to PB samples. The immunological assays were made by fluorochrome-
conjugated monoclonal antibodies and analysis by a three-laser (488, 633, 405 nm)-equipped flow 
cytometer (FacsCanto II, Becton Dickinson, San Jose, CA, USA). A six-color method was applied; 
therefore the following fluorochrome combination was used: fluorescein isothiocyanate (FITC), 
phycoerythrin (PE), peridinin chlorophyll protein complex, phycoerythrin-cyanine 7, 
allophycocyanin, allophycocyanin-cyanine 7. A wide panel of monoclonal antibodies was used that 
always included: CD45, CD13, CD33, CD34, CD117, HLA-DR, CD4, CD14, CD64, CD38, MPO, 
CD11b, CD16, CD15, CD56, CD7, CD19 (all from Becton Dickinson). Cytogenetic analysis was 
made by standard banding methods and by fluorescence in situ hybridization methods. The 
molecular methods, carried out by PCR, included the following fusion genes: AML1/ETO, 
CBFb/MYH11, and BCR-ABL. In addition, FLT3/internal tandem duplication (ITD) was also 
investigated. Patients were studied at the time of diagnosis; one patient was studied during him first 
relapse. 
The AML patient samples BM2985, PB3317, PB2585, PB3924, PB3703, BM2876 and 3 umbilical 
cord blood specimens from healthy donors (CB10, CB15 and CB19) were provided by the Institute 
for experimental cancer research, University-Hospital of Ulm, Ulm, Germany. 
 
Preparation of primary cells 
PB and BM samples of patients and cord blood samples were collected in tubes containing 
preservative-free heparin. Brieﬂy, the primary cells were subjected to Ficoll-Paque density gradient 
separation with Pancoll (PAN Biotech, Aidenbach, Germany) (1,077 g/mL) to isolate mononuclear 
cells (630 g x 30 min) and maintained in culture in IMDM medium (PAN) containing 15% heat-
inactivated bovine serum. The samples always contained >95% blasts. 
 
Preparation of AML patient samples, normal hematopoietic specimens and isolation of LSC 
and HSC. 
In order to isolate CD34+ cells from mononuclear cells, samples obtained from the University-
Hospital of Ulm were then stained with CD34-PE antibody (1:100, Becton Dickinson) and the 
CD34+ population was sorted using FACSAria II cell sorter (Becton Dickinson). Nowadays, the 
CD34+ subpopulation is considered enriched in LSCs and HSCs
160
. The sorted cells population was 
treated for 24h with different concentration of Hemidesmus (0.00-1.55 mg/mL) and piperlongumine 
(0-14 µM). 
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Bio-ID Sample origin Sex Age  Karyotype Molecular 
biology 
AML-1 PB M 78 46,XY[20], 47XY Negative 
AML-2 PB F 66 46,XX[20] FLT3 
AML-3 PB M 85 46,XY[20] Negative 
AML-4 PB M 62 46,XY[20] FLT3-ITD 
BM2985 BM M 25 46,XY[20] FLT3-ITD 
PB3317 PB F 69 46,XX,del(8)(q13q24)[8], 
46,idem,add(17)(p13)[5], 
46,idem,+del(11)(q23),-
17[3], 46,idem, 
der(11)t(11;17)(q13;q11)[2] 
FLT3-ITD 
PB2585 PB M 44 46,XY[20] NPM-1, FLT3-
ITD 
PB3924 PB M 50 46,XY [20] FLT3-ITD 
PB3703 PB F 25 54,XX,+4,+8,+10,+12,+13,+
14,+21,+22[12], 46, XX[8] 
Negative 
BM2876 BM M 60 46,XY,t(3;10)(p11;p14or15),
der(7)t(7;8)(p22;q13),inv(16)
(p13.1q22)[20] 
N-RAS, INV.16 
Table 9: Clinical characteristics of AML patients. 
 
Flow cytometry 
All flow cytometric analyses were performed by using the easyCyte 5HT flow cytometer (Merck 
Millipore, Hayward, CA, USA) or LSRFortessa (Becton Dickinson). 
 
Cell viability 
Cells were treated with different concentrations of Hemidesmus and at different time points. 
Viability was determined immediately after the end of treatment by flow cytometry. Briefly, cells 
were mixed with an adequate volume of Guava ViaCount Reagent (containing propidium iodide, 
Merck Millipore) and allowed to stain 5 min at room temperature. IC50 (inhibitory concentration 
causing cell toxicity by 50% following one cell-cycle exposure) was calculated by interpolation 
from dose-response curve. 
 
Analysis of apoptosis 
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After treatment with different concentrations of Hemidesmus alone, piperlongumine, or the 
combination between Hemidesmus and methotrexate (0.05– 0.25 mM, Sigma), 6-thioguanine (3.75–
30 mM, Sigma), cytarabine (0.10–1.25 mM, Sigma), NAC 10mM aliquots of 2x104 cells were 
stained with 100 µL of Guava Nexin Reagent (Merck Millipore), a pre-maid cocktail containing 
Annexin V-PE and 7-amino-actinomycin D (7-AAD) and, after 20 min of incubation at room 
temperature in the dark, the samples were analyzed by flow cytometry. Camptothecin 2 mM or 
cytarabine 0.5 µM were used as positive controls. The analysis was also performed on Jurkat cells 
treated with 2H4MBAL (10 µg/mL), 3H4MBAL (75 µg/mL) or 2H4MBAC (22.0 µg/mL) and their 
association. 
 
Detection of caspase-8 and caspase-3 activity by flow cytometry 
Active caspases’ detection employed an affinity label methodology, using the caspase-8-preferred 
substrate leucine-glutamic acid-threonine-aspartic acid (LETD) or the caspase-3-preferred substrate 
amino acid sequence aspartic acid-glutamic acid-valineaspartic acid (DEVD) linked to a 
fluoromethylketone (FMK) moiety, which reacts covalently with the catalytic cysteine residue in 
the active enzymatic center. A 6-carboxyfluorescein (FAM) group linked to LETD- or DEVD-FMK 
was used as a reporter. After 24h of treatment with Hemidesmus (0.00-0.93 mg/mL), cells were 
stained with 10 µL of freshly prepared 10X working dilution FAM-LETD-FMK (Merck Millipore) 
or 10 µL of freshly prepared 30X working dilution FAM-DEVD-FMK solution (CHEMICON 
International, Temecula, CA, USA) and incubated for 1h at 37°C, protecting tubes from light. After 
washing, cells were resuspended in 150 µL of 7-AAD diluted 1:200 in 1X working dilution wash 
buffer (Merck Millipore), incubated for 5 min at room temperature in the dark, and analyzed via 
flow cytometry. Camptothecin 2 mM was used as positive control. 
 
Measurement of mitochondrial potential 
Mitochondrial potential was assessed by using JC-1 (5,59,6,69- tetrachloro-1,19,3,39-
tetraethylbenzimidazol-carbocyanine iodide). After 24h of treatment with Hemidesmus 0.93 
mg/mL, 200 µL of cell suspension were treated with 4 µL of 50X staining solution (Merck 
Millipore), containing JC-1 and 7-AAD. Cells were incubated for 30 min at 37°C and analyzed via 
flow cytometry. Valinomycin 0.09 µM was used as positive control. The experiments were also 
performed in the presence of bongkrekic acid (BA, 20 µM, Sigma) for 2h, carboxyatractyloside 
(CATR, 20 µmol/L, Sigma) for 90 min, ADP (500 µM) plus oligomycin (20 µg) for 1h, or 
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cyclosporine A (Cyc A, 1 µM, Sigma) for 1h. The cultures were preincubated with the above 
reported compounds for the indicated times then cultured with and without Hemidesmus. 
 
Analysis of cytochrome c release  
Mitochondrial cytochrome c release was monitored during cell death of digitonin-permeabilized 
cells immunolabeled for cytochrome c. After triggering of apoptosis by Hemidesmus treatment, we 
determined the fraction of cells that have not yet released their mitochondrial cytochrome c and 
were still highly fluorescent, as well as the fraction of apoptotic cells that have already released 
their mitochondrial cytochrome c and, therefore, were much less fluorescent. Cells (1x10
6
) were 
harvested and treated with 1 mL digitonin (100 µg/mL, Sigma) for 5 min on ice. Cells were fixed in 
formaldehyde 4% for 20 min at room temperature, washed three times in PBS 1x and incubated in 
incubation buffer (0.5 g BSA in 100 mL PBS 1X) for 1h. The cells were incubated overnight at 4°C 
with 1:200 anti-cytochrome c monoclonal antibody (clone 7H8.2C12, Becton Dickinson) in 
incubation buffer, washed three times and incubated for 1 h at room temperature with FITC-labeled 
secondary antibody (1:100, Sigma). The cells were then analyzed to quantify FITC binding by flow 
cytometry. Mean fluorescence intensity values were calculated. Non-specific binding was excluded 
by gating around those cells which were labeled by the FITC-conjugate isotype control. 
 
Measurement of intracellular Ca
2+
 ([Ca
2+
]i) 
[Ca
2+
]i was measured using the cell-permeable Ca
2+
 -sensitive fluorescent dye Fluo-3 
acetoxymethyl ester. This dye freely permeates the surface membrane but, following hydrolysis by 
intracellular esterases, is trapped in cells as Fluo-3. The fluorescence intensity of Fluo-3 is enhanced 
after it binds to [Ca
2+
]i and depends on the free calcium concentration
161
. Cells were incubated for 
20 min at room temperature with 4 mM Fluo-3 acetoxymethyl ester diluted in Krebs-Ringer buffer 
[10 mM Dglucose, 120 mM NaCl, 4.5 mM KCl, 0.7 mM Na2HPO4, 1.5 mM NaH2PO4, and 0.5 mM 
MgCl2 (pH 7.4 at 37°C); Sigma]. After washing, the cultures were treated with the indicated 
concentration of Hemidesmus. At the end of incubation, cells were washed in 5 mL of Ca
2+
 -free 
PBS at 37°C, resuspended in 1 mL of Ca
2+
 -free PBS at 37°C and analyzed immediately by flow 
cytometry. The experiments were also performed in the presence of nifedipine (10 µmol/L, Sigma), 
econazole (3 µM, Sigma), thapsigargin (1 µM, Sigma), aristolochic acid (50 µM, Sigma). The 
cultures were preincubated with the above reported compounds for 10 min then cultured with and 
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without Hemidesmus for 10 min. The experiments were performed in Ca
2+
-containing medium 
(RPMI 1640). 
 
Cell proliferation 
Carboxyfluorescein diacetate succinimidyl ester diffuses freely into cells where intracellular 
esterases cleave off the acetate groups, converting it to a fluorescent, membrane-impermeant dye. 
The dye is equally distributed between daughter cells due to covalent crosslinking to proteins 
through its succinimidyl groups. The stain is long lived, allowing the resolution of at least three or 
four cycles of cell division. Propidium iodide is then added to distinguish the live from the dead 
cells. Through the use of differential staining by the two fluorescent dyes, live and dead proliferated 
and unproliferated cells can be distinguished. 25x10
6
 cells were incubated with carboxyfluorescein 
diacetate succinimidyl ester for 15 min at 37°C. After three washes, cell concentration was adjusted 
to 1x10
6
 cells/mL with complete medium. Cells were treated with different concentrations of 
Hemidesmus for 24h. After incubation, cells were treated with 5 mL of cell growth propidium 
iodide reagent (Merck Millipore), incubated in the dark at room temperature for 5 min, and 
analyzed via flow cytometry. 
 
Cell-cycle distribution 
Jurkat were treated for 8, 24, 48h and HL-60 for 24, 30 and 48h with different concentrations of 
Hemidesmus, and then fixed with ice-cold ethanol. Samples were then stained with 200 µL of 
Guava Cell Cycle Reagent (containing propidium iodide, Merck Millipore), incubated at room 
temperature for 30 min, shielded from light, and analyzed via flow cytometry. 
 
Analysis of protein expression 
After treatment for 24h with different concentrations of Hemidesmus (0.00-0.93 mg/mL), 1x10
6
 
cells were fixed and permeabilized by 4% of paraformaldehyde in PBS 1X and 90% of cold 
methanol. They were then incubated with FITC-cyclin A (10:100, Beckman Coulter, Brea, CA, 
USA), p21 (2:100, Abcam, San Francisco, CA, USA), cyclin E (1:100, Abcam), CDK2 (6:100, 
Abcam), Bax (1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bcl-2 (1:100, Santa Cruz 
Biotechnology), PE-conjugated p53 (5:100 BD biosciences, Franklin Lakes, NJ, USA), PSMD11 
(1:100 Abcam), FITC 85 kDa fragment of cleaved poly ADP-ribose polymerase (1:100, PARP, 
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Invitrogen), vascular endothelial growth factor (VEGF) (1:500, Abcam), HIF-1α (1:500, Merck 
Millipore) antibodies. The staining with Noxa (1:10 Abcam), Mcl-1 (1:10 Abcam) antibodies was 
performed after 6h treatment with Hemidesmus due to their rapid protein turnover
162, 163
. The cells 
(except those stained with cyclin A, PARP and p53) were washed and incubated with FITC- labeled 
secondary antibody (1:100, Sigma). Moreover, in order to quantify the expression of membrane 
proteins, aliquots of 1.0x10
6
 cells treated with Hemidesmus were collected, washed twice in ice-
cold 1X phosphate buffer (Sigma) and suspended in 20 µL of FITC-conjugated CD15 [3-fucosyl-N-
acetyllactosamine (3-FAL)] (Biolegend, San Diego, CA, USA), 20 µL of FITC-conjugated CD14 
[glycosylphosphatidilinositol (GPT)- linked] (Biolegend), or VEGFR-2-PE Cy-5.5 (2.5:10, 
Biolegend) and incubated for 30 min in the dark at 4°C. After incubation, the cells were washed 
twice and resuspended in 200 µL of phosphate buffer. The mean fluorescence intensity values were 
calculated. From each sample, 10,000 events were analyzed and non-specific binding was excluded 
by the isotype negative control antibody [FITC Mouse IgG1, k (FC)] (Biolegend). 
 
RNA isolation 
Extraction of total RNA was performed by mirVana 
TM 
miRNA Isolation Kit (Life technologies, 
Waltham, MA, USA) after treatment of cells with different concentrations of Hemidesmus (0.00-
0.93 mg/mL) for 6h, 12h and 24h. The first step of the procedure consists in the denaturation of the 
samples with the lysis buffer. Samples were then purified though a liquid-liquid Acid-
Phenol:Chloroform extraction which also provides the removal of most DNA
164
. Ethanol was added 
to samples and then they were passed through a Filter Cartridge containing a glass-fiber filter which 
immobilizes the RNA. After a series of washing steps finally RNA was eluted with a low ionic 
strength solution. The RNA collected is stable -20°C for several months. 
In order to quantify the amount of extracted RNA was used the NanoVue (GE Healthcare). This 
instrument is able to measure small volume of highly concentrated nucleic acids at the wave length 
of 260nm. 
 
Analysis of RNA quality 
The quality of the RNA extracted has been quantified by microfluidic capillary electrophoresis with 
the Agilent 2100 bioanalyzer (Agilent, Santa Clara, CA, USA). The bioanalyzer is an automated 
bio-analytical device using microfluidics technology that provides electrophoretic separations in an 
automated and reproducible manner
165
. Small portions of RNA are separated in the different 
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channels of the microfabricated chips according to their molecular weight and are detected via 
laser-induced fluorescence detection. The result of the analysis is provided as an electropherogram 
where the amount of RNA of a given size is correlated to the amount of its measured fluorescence. 
Though the use of an algorithm, the software is able to calculate a RNA integrity number (RIN). 
The RIN algorithm is based on a selection of informative features from the electropherograms. For 
this purpose, each electropherogram is divided into nine adjacent segments: a pre-region, a marker-
region, a 5S-region, a fast-region, an 18S-region, an inter-region, a 28S-region, a precursor-region 
and a post-region. Among these, based on their maximum height and ratios, total RNA ratio and the 
28S are the most important features. For classification of RNA integrity, ten categories are defined 
from ≤1 (totally degraded RNA) to 10 (fully intact RNA)166. 
 
cDNA synthesis  
The cDNA synthesis from the extracted RNA was made with the High Capacity cDNA Reverse 
Transcription Kit (Life Technologies). The protocol provides that for each sample, in a sterile, 
nuclease free, thin-walled PCR tube on ice, 10 µL of Master Mix (composition in the table below) 
should be added to 200 µg of RNA. 
RT reaction Mix components 
For each sample 
µL 
10RT Buffer 2 
20x dNTP Mix (100mM 0.08 
10x RT Random Primers 2 
Multiscibe Reverse Transcriptase 1 
RNase Inhibitor 1 
Nuclease free water 3.02 
Total 10 
 
The thermal cycling conditions were: 25 cycles 10 min at 25°C, 120 min at 37°C, 5 min at 85°C, 
and finally 4°C forever. The cDNA was stored at -20°C. 
 
Real Time quantitative RT-PCR (real time qRT-PCR) 
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The real time qRT-PCR is an evolution of the standard PCR (polymerase chain reaction) technique 
commonly used to quantify DNA or mRNA. The real time qRT-PCR is an amplification and 
quantification method where the detection of the target sequence occurs in the exponential 
amplification phase and not at the plateau as occur in the regular PCR. Through the use of specific 
primers labeled with fluorescent dyes, the relative number of copies of a particular DNA or RNA 
sequence can be determined. These probes are oligonucleotides from 20 to 30 base pairs length 
designed to be complementary to the sequence of the target gene that has to be amplified. These 
probes are equipped in the 5’ end sequence with a fluorophore (Reporter or R), usually green, and 
in 3’ with a Quencher (Q), usually red. As long as the probe is inactive, the close gap between the R 
and the Q delete the fluorescence signal of the R. The process could be described in 4 passages: i) 
polymerization: R and Q are attached to the 5’ and 3’ end of a probe; ii) strand displacement, when 
both dyes are attached to the probe, R dye emission is quenched; iii) cleavage, during each 
extension cycle: the DNA polymerase system cleaves the R dye from the probe, iv) completion of 
polymerization: the R dye emits its characteristic fluorescence. The signal is extremely specific 
because the probes do not interfere and the fluorescent signal is present only when the binding 
between probes and target DNA is correct. 
 
Analysis of mRNA  
TaqMan technology was used to analyze mRNA. The qRT-PCR was performed using ABI 7900 
HT (TaqMan
TM
, Life Technologies). 
 
Components 
For each sample 
µL 
TaqMan Universal Master Mix 
(2x) 
12.5 
TaqMan Assay (60x) 1,25 
cDNA 2 
Water 11,25 
Total 26 
 
The thermal cycling conditions were: 10 min at 95°C, 40 cycles: 15 sec at 95°C and 1 min at 60°C. 
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Gene TaqMan Gene Expression Assay 
18S (Endogenous control) Hs99999901_s1 
GADPH (Endogenous control) Hs99999905_m1 
TP53 Hs01034249_m1 
MCL1 Hs01050896_m1 
PMAIP1 (Noxa) Hs00560402_m1 
PSMD11 (Proteasome) Hs00160660_m1 
BAX Hs00180269_m1 
BCL2 Hs00608023_m1 
VEGF Hs00900054_m1 
HIF (HIF-1α) Hs00153153_m1 
KDR (VEGFR-2) Hs00176676_m1 
 
Using the data obtained from the real time qRT-PCR analysis has been made a relative 
quantification of the expression of the genes of interest. This quantification requires an endogenous 
control 18S, used to normalize the quantity of cDNA, and a calibrator represented by our untreated 
sample. The relative expression was calculated as described below: 
- endogenous control normalization: Ct target gene – Ct 18S = ΔCt 
- normalization on the calibrator: ΔCt target gene - ΔCt calibrator = ΔΔCt 
- relative expression of the target gene = 2-ΔΔCt 
 
Detection of levels of reactive oxygen species  
The formation of ROS in Jurkat cells was quantified after 10 min, 1h, 3h and 6h of treatment with 
different concentration of Hemidesmus (0.00-0.93 mg/mL). Briefly, each sample containing 1x10
6
 
cells was treated with 10 µM of 2′,7′-Dichlorofluorescin diacetate (H2DCFDA) (Sigma), incubated 
for 20 min at 37°C, 5% CO2 , in the dark, washed and analyzed by flow cytometry. H2DCFDA is a 
non polar and a non fluorescent compound that diffuses passively through the cellular membrane. In 
presence of ROS, the activation of intracellular esterases results in the cleavage of the diacetate 
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groups and therefore to the formation of the highly fluorescent product dichlorofluorescein 
(DHF)
167
. 
 
Nitro blue tetrazolium (NBT) reduction assay 
This assay was used to evaluate the ability of Hemidesmus (0.00-0.62 mg/mL) to produce 
superoxide when challenged with 12-O,–tetradecanoylphorbol 13-acetate (TPA) after treatment of 
HL-60 for 72h. The assay was performed according to Catino and Miceli
168
. Approximately 1.0x10
6
 
cells were treated with Hemidesmus indicus and freshly prepared TPA/NBT solution (1X phosphate 
buffer containing 0.2% NBT and 200 ng/mL TPA) and incubated for 30 min at 37°C. The reaction 
was stopped by placing the samples on ice for 5 min. Cells were then smeared on glass slides. 
Positive cells reduced NBT yielding intracellular black–blue formazan deposits and this was 
determined by microscope examination (10X total magnification) of 500 cells. The results were 
expressed as percentage of positive cells over total cells. DMSO 1% (v/v) was used as positive 
control. 
 
Adherence to the plastic substrate 
Dish-anchored cells were easily distinguished from the undifferentiated suspended cells. 
Approximately 1.0x10
6
 cells were grown in normal cell growth conditions. After 72h of treatment 
with different concentrations of Hemidesmus (0.00-0.62 mg/mL), the medium was removed and the 
remaining non-adherent cells were gently washed away with 1X phosphate buffer. The number of 
adherent cells was counted on a light microscope. Results were reported as number of attached 
cells
169
. TPA 50 nM was used as positive control. 
 
α-naphthyl acetate esterase activity 
Assay for α-naphthyl acetate esterase was performed using the cytochemical kit from Sigma (91-A). 
Cellular esterases are ubiquitous, apparently representing a series of different enzymes acting upon 
select substrates. Under defined reaction conditions, it may be possible to determine hematopoietic 
cell types, using specific esterase substrates. The assay allows to identify granulocytes from 
monocytes. HL-60 cells were incubated with Hemidesmus (0.00-0.62 mg/mL) and α-naphthyl 
acetate (NAE) in the presence of freshly formed diazonium salt for 72h. Enzymatic hydrolysis of 
ester linkages liberates free naphthol compounds. These couple with the diazonium salt, forming 
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highly colored deposits at sites of enzyme activity
170
. Differentiated cells were assessed by 
microscopic examination of a minimum of 200 cells (in duplicate) for each experiment. 
 
TEM analysis 
After 72h of treatment with Hemidesmus (0.00-0.62 mg/mL), cells were washed and fixed with 
2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.3), post-fixed with 1% OsO4 in the same 
buffer, alcohol dehydrated and embedded in araldite
171
. To obtain better direct ultrastructural 
observations, semithin sections were stained with 1% toluidine blue at 60°C and observed by light 
microscopy. Thin sections were collected on nickel grids, stained with uranyl acetate and lead 
citrate, and analyzed with a Philips CM 10 electron microscope. 
 
In vitro endothelial cell tube formation assay 
The ability of Hemidesmus to influence the endothelial cell tube formation was screened on 
HUVECs using the In Vitro Angiogenesis Assay Kit (Merck Millipore, ECM625). The assay is 
based on culturing cells in an ECMatrix™, a solid gel of basement proteins prepared from the 
Engelbreth Holm-Swarm (EHS) mouse tumor. In particular, ECMatrix™ consists of laminin, 
collagen type IV, heparan sulfate proteoglycans, entactin and nidogen. It also contains various 
growth factors (TGF-β, FGF) and proteolytic enzymes (plasminogen, tPA, MMPs) that occur 
normally in tumors. This gel is optimized for maximal tube-formation, endothelial cells can rapidly 
align and form tube-like structures. Briefly, each well, of a 96-well plate, was coated with 50 µl of 
cold ECMatrix™ solution and the plate was kept at 37°C for 1h to allow the solidification of the 
ECMatrix™. Afterwards, 1x104 HUVECs were seeded in each well in a total volume of 150 µL of 
EGM and treated for 6h in hypoxic or normoxic conditions with various concentrations of 
Hemidesmus (0.00–0.93 mg/mL) and VEGF 10 µg/mL as positive control, and their associations. 
Pictures from three randomly selected fields were taken using a microscope Eclipse E800 Nikon 
(Nikon, Tokyo, Japan). The capillary tube branch points formed were counted in four random view-
field per well. 
 
Invasion assay 
Cell invasion assay was performed with the use of QCM™ 24-well Fluorimetric Cell Invasion 
Assay Kit (ECM554; Merck Millipore) according to the manufacturer’s instructions. In the tumor 
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metastasis process a crucial role is attributed to the invasion of cancer cells through the extracellular 
matrix (ECM). Those cells initiate invasion by adhering and spreading along the blood vessel walls. 
The invasion assay exploits a polycarbonate membrane with an 8 µm pore size coated with a thin 
layer of ECMatrix™, a reconstituted basement membrane matrix of proteins derived from the EHS 
mouse tumor (as described above). The gel, simulating the ECM, occludes the membrane pores and 
physically inhibits the passage of non-invasive cells. Briefly, 1.25x10
5
 HUVECs treated with 
Hemidesmus (0.00-0.93 mg/mL) or untreated were loaded in the upper compartment, while in the 
lower chamber was used EGM supplemented with 10% FBS as chemoattractant, and the plate was 
incubated for 24h in hypoxic and normoxic conditions. Cells able to invade through the membrane 
were detached from the bottom using a Cell Detachment Buffer, and then were fixed and stained 
with Staining buffer constituted by CYQuant GR Dye. The fluorescence of the invaded cells was 
evaluated by a fluorescence plate reader (Tecan, Männedorf, Swiss) using 480/520 nm filter set. 
The invaded cell number was reported as relative fluorescence variation compared to the control. 
Figure 10: Schematic overview of the invasion and migration assays. 
 
Migration assay 
In order to quantify the migration potential of HUVECs treated with Hemidesmus (0.00-0.93 
mg/mL) in hypoxic and normoxic condition was used the QCM™ 24-well Fluorimetric Cell 
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Migration Kit (ECM509; Chemicon). Cell migration is a crucial function of normal cellular 
processes, like embryonic development, angiogenesis, wound healing, immune response, and 
inflammation. An unregulated cell migration can cause vascular disease and it is considered 
fundamental for the initiation of the metastatic process
172
. The assay was performed in a migration 
chamber that includes an 8 µm pore size polycarbonate membrane. This pore size supports optimal 
migration for most epithelial and fibroblast cells. In particular, 2.00x10
5
 HUVECs cells treated with 
o without Hemidesmus (0.00-0.93 mg/mL) were loaded in the upper compartment, while in the 
lower chamber was used EGM supplemented with 10% FBS as chemoattractant, and the plate was 
incubated for 6h. Cells able to migrate through the membrane were detached from the bottom using 
a Cell Detachment Buffer, and afterwards fixed and stained with Staining buffer constituted by 
CYQuant GR Dye. The fluorescence of the migrated cells was evaluated by a fluorescence plate 
reader (Tecan) using 480/520 nm filter set. The migrated cell number was reported as relative 
fluorescence variation compared to the control. 
 
Colony-forming unit (CFU) assay  
This method was used to determine the potential of sorted CD34+ from AML and healthy donor 
cord blood samples to form colonies in a methylcellulose based medium after 24h treatment with 
Hemidesmus (0.00-1.55 mg/mL) and piperlongumine (0-14 µM). 1×10
5
 cells/mL AML cells and 
1x10
3
 cells/mL
 
cord blood cells were mixed with MethoCult GF H4434 containing 50 ng/mL stem 
cell factor, 10 ng/mL GM-CSF, 10 ng/mL IL-3, 50 ng/mL G-CSF, and 3 units/mL erythropoetin 
(StemCell Technologies) in a poly tube. Then 1 mL mixtures were placed into each of two 35 mm 
culture dishes using a 3 mL syringe and a 16 gauge blunt-end needle. In order to spread the 
methylcellulose evenly the dishes were gently rotated and placed in a 100 mm petri dish with a third 
one full of sterile water. These plates were incubated for 14 days at 37°C and 5% CO2, and then was 
evaluated the colony formation capability of the cells through a microscopic analysis (40X 
magnification, Nikon Instruments Inc, Amsterdam, Netherland). The colonies were counted and 
separated in 4 groups on the base of their morphological characteristics. 
- CFU-GEMM: Colony forming units of granulocytes, erythrocytes, macrophages and 
megakaryocytes progenitor. 
- BFU-E: Burst forming unit erythroid. 
- CFU-GM: Colony forming units of granulocyte-macrophage progenitor. 
- Cluster: Not yet colonies (<30 cells). 
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Figure 11: Pictures of three types of colonies. 
 
Statistical analysis 
All results are expressed as the mean of at least 3 biological replicates. Differences among 
treatments were evaluated by one-way or two-way ANOVA, followed by Dunnett or Bonferroni 
post-test, using GraphPad InStat version 5.00 (Graphpad Prism, San Diego, CA, USA). P,0.05 was 
considered significant. Interactions between Hemidesmus and anticancer drugs were classified using 
the combination index (CI). CI analysis provides qualitative information on the nature of drug 
interaction, and CI, a numerical value calculated as described in the following equation, also 
provides a quantitative measure of the extent of drug interaction
173
. 
 
CA,x and CB,x are the concentrations of drug A and drug B used in combination to achieve 6% 
drug effect. ICx,A and ICx,B are the concentrations for single agents to achieve the same effect. A 
CI of less than, equal to, and more than 1 indicates synergy, additivity, and antagonism, 
respectively. 
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Chapter 4 
Results 
 
Hemidesmus indicus contains 2H4MBAL, 3H4MBAL and 2H4MBAC 
Hemidesmus was found to contain 2H4MBAL, 3H4MBAL and 2H4MBAC (Fig. 12A). NMR data 
on the decoction and on the enriched fraction are shown in Fig. 12B and 12C. The amounts found in 
the decoction (31 mg/mL) were: 0.0025±0.001 mg/mL for 2H4MBAL, 0.0018±0.003 mg/mL for 
3H4MBAL, 0.0022±0.005 mg/mL for 2H4MBAC. The analyses were performed on the decoction 
obtained from three different batches. The difference among the batches in the phytomarker content 
was not significant. 
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Figure 12: HPLC chromatogram (A), NMR analysis (B) of Hemidesmus and NMR spectrum of an 
enriched fraction obtained by Soxhlet extraction, compared with 
1
H NMR evidences of each 
reference standard (C). 
 
Hemidesmus indicus induces apoptosis in Jurkat cells 
Based on the cytotoxicity results (data not shown), cells were treated with concentrations of 
Hemidesmus indicus similar or smaller than the IC50 (0.62, 0.93, 1.55 mg/mL) for 24 h. 
Hemidesmus treatment induced apoptosis at all the concentrations tested and in all tested cell lines 
(Fig. 13A). For example, after treatment of Jurkat cells with 0.93 mg/mL of Hemidesmus, the 
incidence of apoptotic cells was 36.9% (versus 4.8% in the control). They increased to 44.8% after 
treatment with the highest dose studied (Fig. 13B). However, 1.55 mg/mL of Hemidesmus induced 
a significant increase of necrotic cells (Fig. 13B). Similar results were recorded for the other cell 
lines (Fig. 13A). Since the highest increase in apoptotic cells with respect to the control was seen in 
Jurkat cells, the study continued on this cell line. For excluding necrotic events, concentrations of 
up to 0.93 mg/mL were used. No induction of apoptosis was observed in Jurkat cells following 
treatment with 2H4MBAL, 3H4MBAL or 2H4MBAC. The association between the two aldeydes 
and the acid induced a significant increase in the apoptotic cell fraction (16% of apoptotic cells vs 
3% in the untreated sample) (Fig. 13C). 
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Figure 13: Induction of apoptosis by Hemidesmus indicus. Fraction of viable, apoptotic and 
necrotic cells in different leukemic cell lines (A) and in Jurkat cells (B). Induction of apoptosis by 
single phytomarkers and their association in Jurkat cells (C). 
Hemidesmus indicus showed the ability to affect caspase-3 but not caspase-8 activity and activate 
PARP. Caspase-3 activity was significantly increased in cells treated with Hemidesmus (0.93 
mg/mL). The percentage of cells with caspase-3 activated in non-treated cultures was about 8%, 
which was increased to 17.4% in cells treated with Hemidesmus 0.93 mg/mL (Fig. 14A). An 
important reporter for caspase-3 activation is PARP. Hemidesmus (0.93 mg/mL) induced an 
increase of PARP cleavage of about 2.7 times compared to the control (Fig. 14B). Figure 14C 
shows a representative cytogram where two well-defined cell populations are distinguishable in 
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Hemidesmus-treated cells after labeling with FITC 85 kDa fragment of cleaved PARP. Only one 
population characterized by a lower fluorescence intensity (white histogram) was recorded in 
untreated cells. Unstimulated Jurkat T cells incubated with FAM-LETD-FMK generated a low 
detectable fluorescence signal, indicating that levels of active caspase-8 were low in these cells. 
Caspase-8 activity increased after treatment with the positive control camptothecin but remained at 
basal levels after treatment with 0.93 mg/mL of Hemidesmus (Fig.14D). 
 
Figure 14: Activation of caspase-3(A), cleavage of PARP (B–C) and activation of caspase-8 (D) 
following treatment with Hemidesmus for 24h. 
In order to determine the ability of Hemidesmus indicus to disrupt mitochondrial transmembrane 
potential, Jurkat cells were treated with 0.93 mg/mL of Hemidesmus indicus. The treatment resulted 
in a significant break-down of the mitochondrial membrane potential. The effect of Hemidesmus 
0.93 mg/mL resulted even greater than that observed for valinomycin, used as positive control 
(Figure 15A). Cytochrome c release from mitochondria to cytosol is a hallmark of apoptosis and is 
used to characterize the mitochondria-dependent pathway of this type of cell death. After treatment 
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with Hemidesmus (0.93 mg/mL), the fraction of cells that retained their mitochondrial cytochrome 
c, or the highly fluorescent cells, gradually decreased and emerged as a population of low 
fluorescent cells (Fig. 15E). Since the mitochondrial pathway resulted clearly involved in the pro-
apoptotic activity of Hemidesmus, we investigated whether classic adenine nucleotide translocator 
modulators, such as CATR and BA, or Cyc, which targets cyclophilin D in the matrix, could 
interfere with the action of Hemidesmus on mitochondrial depolarization. Mitochondrial 
depolarization induced by Hemidesmus was not specifically inhibited by BA, CATR or Cyc A (Fig. 
15B). 
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Figure 15: Alterations in mitochondrial membrane permeability in absence (A) and presence (B) of 
inhibitors following treatment with Hemidesmus 0.93 mg/mL. Fraction of cells with increased 
[Ca
2+
]i following 3 or 24h culture in the absence or presence of Hemidesmus (0.93 mg/mL) (C), 
flow cytometric analysis of [Ca
2+
](D) and cytochrome c (E) following 24h culture in the absence or 
presence of Hemidesmus (0.93 mg/mL). 
Elevation of cytosolic Ca
2+
 is sufficient to induce mitochondrial permeability transition pore 
opening and brings to apoptosis in different cell systems
161
. We therefore studied the ability of 
Hemidesmus to modulate [Ca
2+
]i. Following 24 h-treatment with Hemidesmus, [Ca
2+
]i was found to 
be about 5 times higher than that of the controls (Fig. 15C). Short times of exposure (3h) induced a 
smaller but still significant increase in [Ca
2+
]i (Fig. 15C). The recorded mean fluorescence intensity 
values clearly indicated two defined cell populations with different intracellular calcium levels (Fig. 
15D). In Hemidesmus-treated cells, the mean fluorescence values were 162.88 and 6.49, 
respectively (Fig. 15D). Experiments were performed to explore the pathway of Hemidesmus-
induced [Ca
2+
]i raise. The removal of extracellular Ca
2+
 did not abolish the [Ca
2+
]i raise induced by 
Hemidesmus. Some Ca
2+
 influx inhibitors, such as nifedipine and econazole, failed to affect 
Hemidesmus-induced [Ca
2+
]i rise in Ca
2+
-containing medium (Fig. 16A and B). In contrast, 
aristolochic acid and thapsigargin significantly increased Hemidesmus-induced [Ca
2+
]i rise (Fig. 
16C and D).  
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Figure 16: Effect of different inhibitors on Hemidesmus-induced [Ca
2+
]i raise. Effects of nifedipine 
(A), econazole (B), aristolochic acid (C) and thapsigargin (D) on Hemidesmus-induced [Ca
2+
]i 
raise. 
Moreover, Hemidesmus indicus showed the ability to stymulate the intracellular formation of ROS. 
We found that Jurkat treated for 10 min, 1h, 3h and 6h with Hemidesmus a dose-dendently 
increased in the formation of ROS (Fig. 17 A-D). In order to prove the role of the ROS formation in 
the pro-apoptotic activity evoked by Hemidesmus, we studied its association with NAC, a well-
known antioxidant agent, in terms of induction of apoptosis. The association resulted in a 
significant reduction of the pro-apoptotic acvtivity of Hemidesmus (Fig. 17E). 
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Figure 17: ROS relative expression after treatment of Jurkat cells for 10 min (A), 1h (B), 3h (C) 
and 6h (D) with Hemidesmus. Induction of apotptosis by Hemidesmus in absence and presence of 
NAC after treatment of Jurkat cells for 24h (E).  
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In order to define the mechanism of action whereby Hemidesmus indicus induces apoptosis in 
Jurkat cells, the pre- and post- transcriptional modulation of some proteins, involved in the 
regulation of the apoptotic intrinsic pathway, has been analyzed. The quality of the total RNA 
extracted, checked with the BioAnalyzer 2100, reported RIN values between 9 and 10, showing a 
good RNA integrity at all tested concentrations. 
The p53 tumor suppressor promotes apoptosis through transcription-dependent and -independent 
mechanisms that act in concert to ensure that cell death program proceeds efficiently. Its 
inactivation can promote tumor progression and chemoresistance
174
. Hemidesmus did not induce 
significant variation in the expression of p53 (Fig. 18A), while showed a clear dose-dependent 
down-regulation of p53 mRNA (Fig. 18B). Hemidesmus 0.93 mg/mL induced the highest down-
regulation in the p53 mRNA level after 6h of treatment (0.53±0.05).  
 
Figure 18: p53 protein relative expression after treatment of Jurkat cells with Hemidesmus for 24h. 
p53 mRNA relative expression following 6h, 12h and 24 h culture with Hemidesmus (B). 
The study of the pro- and anti-apoptotic proteins modulated by Hemidesmus continued analyzing its 
ability to affect the expression of Noxa and Mcl-1 at protein and gene level and their ratio. 
Hemidesmus did not induce any modulation in the expression of Noxa (Fig. 19A). On the other 
hand, a clear, dose-dependent up-regulation of the gene expression of PMAIP1 was induced by 
Hemidesmus at all treatment times (Fig. 19B). The highest expression of PMAIP1 was reported 
after treatment of Jurkat cells for 6h with Hemidesmus 0.93 mg/mL (2.68±0.10). The ability of 
Hemidesmus to increase the mRNA levels of PMAIP1 appeared time-dependent. Indeed, increasing 
the time of treatment reduced the induction of PMAIP1 (Fig. 19B). Moreover, Hemidesmus reduced 
Mcl-1 protein expression after 6h treatment at all tested doses (Fig. 19C). The mRNA expression of 
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MCL1 was increased by treating cells with Hemidesmus at all time points and reached the highest 
effect after 6h treatment with Hemidesmus 0.93 mg/mL (1.99±0.20) (Fig. 19D). Noxa/Mcl.1 
proteins ratio was determined by using the relative expression of both proteins normalized to the 
untreated sample (control) after 6h treatment with Hemidesmus. The Noxa/Mcl-1 ratio was 
significantly higher compared to the control group and reached its peak at the concentration 0.62 
mg/mL (1.67±0.20) (Fig. 19E). 
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Figure 19: Relative expression of Noxa and Mcl-1 protein levels (A, C) and variation of Noxa/Mcl-
1(E) after 6h treatment of Jurkat cells with Hemidesmus. Modulation of Noxa (B) and Mcl-1 (D) 
mRNA following 6h, 12h and 24h culture with Hemidesmus. 
Furthermore, Hemidesmus indicus affected the expression of Bax and Bcl-2 protein levels. Both 
Bax (Fig. 20A) and Bcl-2 (Fig. 20B) expression was found to be significantly increased in treated 
cells. Bax-to-Bcl-2 ratio was determined by using the mean fluorescence intensity value of 
Hemidesmus-treated cells that was normalized to the mean fluorescence intensity of untreated 
(control) samples within each group (Fig. 20C). The Bax-to-Bcl-2 ratio was significantly higher 
than the control group. The expression levels of BAX and BCL2 were strongly affected by the 
treatment with Hemidesmus. Both genes were down-regulated in a dose-dependent manner at all 
time points (6h, 12h and 24h) (Fig. 20D-E). Notably, the mRNA down-regulation of Bax was more 
pronounced in samples treated for 24h with Hemidemsus 0.93 mg/ml, while the expression of Bcl-2 
was lowest after 12h treatment with the same concentration. 
 
Figure 20: Relative expression of Bax and Bcl-2 protein levels (A, B) and variation of Bax-to-Bcl-2 
ratio (C) after 24h treatment of Jurkat cells with Hemidesmus. Modulation of Bax (D) and Bcl-2 (E) 
gene expressions following 6h, 12h and 24h culture with Hemidesmus. 
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The differential regulation of Bax and Bcl-2 of mRNA and protein level observed for Hemidesmus 
encouraged specific studies to understand its ability of inhibiting proteasome. The ubiquitin-
proteasome system is an important regulator of cell growth and apoptosis. Several proteasome 
inhibitors exert anti-tumor activity in vivo and potently induce apoptosis in tumor cells , including 
in those resistant to conventional chemotherapeutic agents
175
. The treatment of Jurkat cells with 
Hemidesmus caused a reduction in the protein expression of the 26S proteasome (0.53±0.02) (Fig. 
21A). The proteasome inhibition evoked by Hemidesmus resulted comparable with that of two well-
known proteasome inhibitors, like MG132 0.5 µM (0.48±0.02) and bortezomib 10µM (0.54±0.02) 
(Fig. 21A). Furthermore, Hemidesmus showed a dose-dependent inhibition of the proteasome 
(PSMD11) mRNA expression, after 12h and 24h treatment (Fig. 21B). Hemidesmus showed the 
highest inhibitory effect after 24h treatment and at 0.93 mg/mL induced a reduction in the gene 
expression of PSMD11 of 0.52±0.04. 
 
Figure 21: PSMD11 protein relative expression after treatment of Jurkat cells with Hemidesmus, 
bortezomib and MG132 (A) for 24h. Reduction of the PSMD11 mRNA relative expression following 
12h and 24h culture in presence of Hemidesmus (B). 
 
Hemidesmus indicus perturbs Jurkat cell proliferation  
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Hemidesmus significantly suppressed the progression of cells into the cell cycle (Fig. 22A). At 0.93 
mg/mL, Hemidesmus suppressed Jurkat proliferation by 30% and at 1.9 mg/mL by 66%. At 3.1 
mg/mL, cell-cycle progression was almost completely suppressed. By looking at the fraction of live 
and dead proliferated and unproliferated cells, we observed that more than 90% of the cells were 
proliferated and dead (propidium iodide-positive) at the highest concentration of Hemidesmus 
tested. These results indicate that the cytotoxicity of Hemidesmus against Jurkat cells was 
attributable to both the cytostatic effect causing the prevention of cell proliferation and the apoptotic 
and/or necrotic effect causing the loss of cell viability. At all concentrations, addition of 
Hemidesmus caused a dose-related accumulation of cells in the S phase (Fig. 22B-D). The 
immediate effects (8h) appeared primarily as an increase in the proportion of cells in the S phase of 
the cell cycle (from about 16% to 22%) accompanied by a slight compensatory decrease in G1 phase 
cells. Longer exposure (24h) led to a further decrease in the proportion of G1 cells, while the 
percentage of cells in S phase increased from 20% to 29%. Prolonged (48h) exposure appeared as a 
decrease in G1 phase cells (from 62% to 43%), an unaffected fraction of G2/M phase cells and a 
marked increase in the proportion of S cells (from 20 to 40%).  
Since Hemidesmus was found to selectively alter the distribution of Jurkat cells in the cell cycle, we 
evaluated its effects on the expression of cell regulatory proteins including cyclins A2 and E, CDK2 
and p21. As shown in Figure 22E, the proteins specific for CDK2, cyclin A2, cyclin E, and p21 
were easily detectable in continuously growing Jurkat cells. Among the protein levels, those of 
cyclin A2 remained relatively constant, whereas those of both cyclin E and p21 significantly 
increased after treatment with Hemidesmus indicus for 24h (Fig. 22E). Moreover, treatment with 
Hemidesmus greatly decreased the expression of CDK2 (Fig. 22E). 
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Figure 22: Cell proliferation (A), cell-cycle distribution (B-D), and cyclin A2, cyclin E, CDK2, and 
p21 protein levels (E) following 24h culture in the absence or presence of Hemidesmus. 
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Hemidesmus indicus increases the antitumor efficacy of 6-thioguanine, cytarabine and 
methotrexate 
To investigate whether Hemidesmus could increase the cytotoxicity of some anticancer drugs, cells 
were treated with a combination of 6-thioguanine, cytarabine or methotrexate plus Hemidesmus. We 
measured the pro-apoptotic effect of the combination using doses of Hemidesmus that induced 
submaximal toxicity (0.31 mg/mL). This can allow observing potential additive or synergistic 
effects. Combination of Hemidesmus with 6-thioguanine, cytarabine or methotrexate had a 
synergistic or additive pro-apoptotic effect compared with each drug present alone (Fig. 23A-C). 
For instance, when 6-thioguanine was used alone, a 33% of apoptotic cells (versus 5% in the 
untreated cultures) was observed at the highest concentration tested. When it was used together with 
0.31 mg/mL of Hemidesmus, a 51% of apoptotic cells was induced (Fig. 23A). Similarly, cytarabine 
alone at 1.25 mM induced a 35% of apoptotic cells (versus 4% in the untreated culture), but co-
presence of Hemidesmus produced a 48% of apoptosis (Fig. 23B). The CI was found to be 0.6 for 6-
thioguanine and 0.38 for cytarabine. The effect of Hemidesmus was also observed on cells treated 
with methotrexate. Treatment with methotrexate alone slightly affected cell viability. The % of 
apoptotic cells observed following treatment with methotrexate was similar to that of untreated 
cultures (Fig. 23C). Because of the relative insensitivity of Jurkat cells to methotrexate, we could 
not calculate a CI. In this case, the interaction between Hemidesmus and methotrexate was 
classified using the fractional inhibition method as follows: when expressed as the fractional 
inhibition of cell viability, additive inhibition produced by both inhibitors (i) occurs when i1,2 = i1 + 
i2; synergism when i1,2 > i1 + i2; antagonism when i1,2 < i1 + i2
176
. Using this method, the interaction 
between Hemidesmus and methotrexate was additive. 
 
Hemidesmus indicus induces cytotoxic effects on mononuclear cells isolated from AML 
patients 
We examined the effect of Hemidesmus on the viability of AML cells (Fig. 23D). Hemidesmus 
produced a cytotoxic effect in all samples tested. Viability of cells treated with Hemidesmus during 
24h decreased from 97.5% in the control to 55.0% in the cells treated with Hemidesmus . To assess 
whether cell death induced by Hemidesmus was due to apoptosis, we measured the exposure of 
membrane phosphatidylserine by flow cytometry. As shown in Figure 23D, Hemidesmus at 0.93 
mg/mL induced a 3-fold increase in apoptotic cell fraction in patients AML-1, AML-2 and AML-3, 
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and a 4-fold increase in AML-4 patient. Interestingly, the response to Hemidesmus was more 
pronounced on blasts obtained from a recidivant patient (AML4) (Fig. 23D). 
 
Figure 23: Fraction of apoptotic cells induced by 6-thioguanine (A), cytarabine (B) or methotrexate 
(C) following 24 h culture in the absence or presence of Hemidesmus (0.31 mg/mL) and fraction of 
apoptotic cells induced by Hemidesmus on mononuclear cells isolated from AML patients (D). 
 
Hemidesmus indicus induces apoptosis as well as differentiation of HL-60 cells 
Hemidesmus decreased HL-60 viability and the IC50 value calculated after 30h of treatment was 
1.52 mg/mL (Fig. 24A). The induction of apoptosis was evaluated for concentrations similar or 
smaller than the IC50 (0.00–1.55 mg/mL). The incidence of apoptotic cells after 30h was statistically 
significant starting from the concentration of 0.62 mg/mL (11.6% vs 4.6% in the control). The 
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highest percentage of apoptotic cells (23.0%) was observed at the highest concentration tested, 
which resulted higher than that induced by cytarabine 0.5 µM. However, a significant fraction of 
necrotic cells was also recorded starting from the concentration 0.93 mg/mL (Fig. 24B). 
 
Figure 24: Cytotoxicity (A) and fraction of viable, apoptotic and necrotic cells (B) after treatment 
with Hemidesmus indicus at the indicated doses for 30h. 
Hemidesmus is also able to alter cell-cycle progression. To define the rate at which Hemidesmus 
perturbed cell-cycle progression, cell cycle was evaluated at different time points. The effect of 
Hemidesmus was time-dependent. The early effect, observed at a concentration of 0.47–1.24 
mg/mL, appeared as an increase in the percentage of cells in G0/G1 and S phases starting from the 
concentration 0.62 mg/mL, accompanied by a compensatory decrease in G2/M phase cells. The 
highest effect was observed at the highest dose tested, where the percentage of cells in G0/G1 phase 
reached 23%, in S phase 31% and in G2/M phase about -53% (Fig. 25). Longer exposure (30h) led 
to an increase of cells in the G0/G1 and S phases. The effect was significant starting from the 
concentration of 0.93 mg/mL Hemidesmus (G0/G1: 28%; S: 14%). A decrease of cells in G2/M 
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phase starting from 0.62 mg/mL was also observed (from -15% to -59%) (Fig. 25). Prolonged 
exposure (48h) appeared as a marked increase in the proportion of cells in G0/G1 phase starting 
from 0.47 mg/mL (about 6%), that reached the highest level at 1.24 mg/mL (about 50%). A 
decrease in the percentage of cells in S and G2/M phases was also recorded (Fig. 25). 
 
Figure 25: Effects of Hemidesmus indicus on cell-cycle distribution following 24h (A), 30h (B) and 
48h (C) of treatment with Hemidesmus expressed as percentage of relative variation compared to 
untreated cells (control). 
The analysis of cytodifferentiation has to be performed at concentrations where cell viability is 
higher than 80%
177
. For the analysis of cytodifferentiation induced by Hemidesmus after 72h of 
treatment, HL-60 cells were treated with up to 0.62 mg/mL of Hemidesmus, where we recorded a 
cell viability of 82%. At 0.93 mg/mL cell viability was 48%. NBT reduction, a marker for 
granulocyte/monocyte differentiation, revealed that Hemidesmus induced a dose-dependent 
differentiation of HL-60 cells (Fig. 26A). After treatment with Hemidesmus 0.62 mg/mL, the 
fraction of NBT-positive cells was 36.56%±0.78 compared to 5.62%±0.47 in the control, thus 
comparable to DMSO (43.88%±0.80), used as positive control (Fig. 26A). Hemidesmus 0.62 
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mg/mL also induced an increase in the number of adherent cells by over 8- fold (Fig. 26B). This 
suggests that Hemidesmus is able to stimulate differentiation into monocyte/macrophage. The 
increased number of α-naphthyl-acetate-esterase-positive cells confirmed the differentiation toward 
the monocyte/macrophage. The highest effect was observed at the highest concentration of 
Hemidesmus (23.50%±0.84 vs 3.00%±0.52 in the control) (Fig. 26C). 
To confirm the ability of Hemidesmus to induce differentiation, the expression of two specific 
monocyte/granulocyte and monocyte/macrophage markers, CD15 and CD14 respectively, was 
analyzed. Cells treated with 0.62 mg/mL of Hemidesmus showed a CD15 mean fluorescence of 
2.32-fold higher than untreated cells (Fig. 26D). The mean fluorescence of CD14 was 2.45-fold 
higher compared to the control at 0.62 mg/mL and 1.50-fold higher at 0.31 mg/mL (Fig. 26E). The 
cytodifferentiative potential of Hemidesmus was further detailed by TEM analysis. Figure 27 shows 
cell differentiation towards granulocyte and/or macrophage lineages. Myeloid cell granule 
maturation, at ultrastructural level, occurs through a progressive condensation of granule content 
from a loose, scarce electrondense substance, to a dense compact material. In Hemidesmus-treated 
HL60 cells, 0.2–0.5 mm immature granules, scattered throughout the cytoplasm and consistently 
absent in control cells, are clearly recognizable in A. Occasional 0.1–0.3 mm granules, containing a 
uniform, electron-dense material, can be also revealed and correspond to a further differentiated 
granule form (A, B). The presence of larger empty vacuoles (C), typical a phagocytic process, 
suggests a progressive macrophage differentiation, as also confirmed by the observation of large 
cells, with flattened polymorph nucleus, phagocyting necrotic ones (D). 
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Figure 26: Dose-dependent effects of Hemidesmus indicus on HL-60 cell differentiation as 
evaluated by NBT-reducing ability (A), cell adhesion (B), a-naphthyl acetate esterase activity (C) 
and expression of CD15 (D) and CD14 (E) markers. 
73 
 
 
Figure 27: TEM of HL-60 cells after Hemidesmus indicus treatment. Forming (*) and mature (g) 
granules indicate the granulocytic differentiation (A, B). Cytoplasmic vacuoles (v) and 
phagocytosis patterns (c) evidentiate the macrophagic properties (C, D). A, B, bar=5 µm; C, D, 
bar=1 µm. 
 
Hemidesmus indicus inhibits angiogenesis as well as reduces invasion and migration of 
HUVECs 
In order to determine the effect of Hemidesmus indicus on the proliferation of HUVECs in 
normoxic (Fig. 28A) and hypoxic (Fig. 28B) conditions, these cells were treated with different 
concentration of Hemidesmus (0.00-0.93 mg/mL) for 6h and 24h. The treatment with Hemidesmus 
for 6h induced a significant reduction in cell proliferation only in normoxic condition and at the 
highest tested dose (68.7% proliferating cells). On the other hand, after 24h of treatment, in both O2 
conditions, a significant reduction of cell growth was induced by Hemidesmus 0.93 mg/mL 
(normoxia: 49.6%, hypoxia: 75.9% proliferating cells). To exclude any possible effect of 
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Hemidesmus on angiogenesis connected with the reduction of viability and induction of apoptosis, 
the pro-apoptotic potential of Hemidesmus on HUVECs was screened. In both normoxic (Fig. 28C) 
and hypoxic (Fig. 28D) conditions none of the Hemidesmus tested concentrations showed a 
significant increase in the fraction of apoptotic cells. 
 
Figure 28: Cell proliferation (A-B) and induction of apoptosis (C-D) following 6h and 24h culture 
in normoxic (A, C) and hypoxic (B, D) conditions with Hemidesmus. 
The ability of HUVECs, treated with Hemidesmus (0.00–0.93 mg/mL), VEGF 10µg/mL used as 
positive control, or their association, to migrate, attach each other, and form tube structure on 
ECMatrix™ are shown in the Figure 29A. This clearly demonstrates that Hemidesmus at the highest 
tested concentrations (0.62 and 0.93 mg/ml), in both hypoxic and normoxic conditions, strongly 
inhibits tube formation. The count of the tube branch points formed by HUVECs following 
different treatments showed the ability of Hemidesmus 0.62 mg/mL to reduce significantly the 
branch point number more in normoxic then in hypoxic conditions (0.17±0.07 vs 0.22±0.13) 
compared to the untreated sample (Fig. 29B). The association Hemidesmus 0.62 mg/mL-VEGF 
showed similar effects with a reduction of the branch point number in normoxia (0.21±0.06) and 
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hypoxia (0.24±0.20) compared to the VEGF control (Fig. 29C). Moreover, in samples treated with 
Hemidesmus 0.93 mg/mL in both normoxic and hypoxic conditions, HUVECs were not able to 
form hollow tube-like structures. Thus, branch point could not be determined (Fig. 29B-C). 
 
Figure 29: Microscopic photographs of tube formation on reconstituted basement membrane gel 
after 6h of incubation in normoxia and hypoxia. (A a, a1) untreated control; (A b, b1) VEGF 10 
µg/mL control; (A c, c1) Hemidesmus 0.62 mg/mL; (A d, d1) Hemidesmus 0.93 mg/mL. Relative 
variation of the branch point number of HUVECs treated for 6h in normoxic and hypoxic 
conditions with Hemidesmus, VEGF (B) and their association (C). 
 
The ability of Hemidesmus to inhibit angiogenesis was confirmed by checking its ability to induce a 
post-transcriptional and post-translational modulation of proteins involved in the regulation of the 
vessel formation process. The expression of VEGF, VEGFR2 and HIF-1α was quantified by mean 
fluorescence. Treatment with Hemidesmus showed, in hypoxic and normoxic conditions, a dose-
dependent down-regulation of VEGF that reached the maximum effect at the highest tested 
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concentration with a decrease of its relative expression of 0.81±0.02 in normoxia and 0.77±0.11 in 
hypoxia (Fig. 30A). Hemidesmus did not show any effect in normoxic condition on the expression 
of VEGFR2 and HIF-1α (Fig. 30B-C). On the other hand, in hypoxic conditions, treatment with 
Hemidesmus down-regulated the expression of all three proteins at all tested doses. In particular, the 
highest effects on VEGFR2 and HIF-1α were observed after treatment with Hemidesmus 0.93 
mg/mL that induced a reduction of their expressions of 0.60±0.07 and 0.83±0.03, respectively (Fig. 
30B-C). Treatments with Hemidesmus in hypoxic conditions induced a significant reduction in the 
expression of VEGFR2 and HIF-1α compared to the same treatments conducted at normal O2 
pressure (Fig. 30B-C). 
 
Figure 30: Relative protein expression of VEGF (A), VEGFR2 (B) and HIF-1α (C) after treatment 
of HUVECs for 6h with Hemidesmus. 
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Hemidesmus regulated VEGF, KDR and HIF expression. A dose-dependent down-regulation was 
observed, particularly marched for HIF-1α and KDR in hypoxic conditions (Fig. 31B-C). The 
highest inhibitory effect was observed after treatment of HUVECs with Hemidesmus 0.93 mg/mL, 
both in normoxic and hypoxic conditions. 0.93 mg/mL of Hemidesmus induced a stronger down-
regulation on HIF-1α mRNA in hypoxia than in normoxia (0.07±0.04 vs 0.25±0.061, respectively) 
(Fig. 31C). With regard to VEGF mRNA, it was not possible to observe any significant modulation 
(Fig. 31A). 
 
Figure 31: Relative mRNA expression of VEGF (A), KDR (B) and HIF (C) after treatment of 
HUVECs for 6h with Hemidesmus. 
Migration plays an important role in angiogenesis and is a prerequisite for tumor-cell invasion and 
metastasis. We explored whether Hemidesmus was able to inhibit invasion and migration of 
HUVECs using a transwell chamber migration system with a polycarbonate membrane. In 
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normoxic conditions, the inhibition of migration and invasion was more pronounced than in 
hypoxia (Fig. 32A-B). The migrated and invaded cell number relative variation was obtained from 
the comparison between their fluorescence signal in treated samples and the untreated control. 
Actually, at normal oxygen concentration conditions, Hemidesmus 0.93 mg/mL after 6h of 
treatment led to a reduction of the migrated cell number relative variation to 0.65±0.01. The 
invaded cell number relative variation was 0.50±0.03. The same treatment conduced in hypoxic 
conditions showed a reduction of the capability of migration (0.789±0.003) and invasion 
(0.63±0.07) (Fig. 32A-B). Notably, the ability of Hemidesmus to inhibit cellular invasion was more 
pronounced in normoxia rather than hypoxia. This effect was particularly pronounced at the lowest 
treatment dose of Hemidesmus. 
 
Figure 32: Relative variation of migrated (A) and invaded (B) cell number following culture of 
HUVECs in normoxic and hypoxic conditions with Hemidesmus. 
 
Hemidesmus indicus and piperlongumine have a selective action toward LSC 
The selectivity of action of Hemidesmus and piperlongumine in the eradication of LSC was 
evaluated in terms of pro-apoptotic potential and inhibition of the colony formation capability. After 
treatment for 24h of the CD34+ subpopulation of 6 AML patients, Hemidesmus (Fig. 33A-B) and 
piperlongumine (Fig. 34A-B) showed the ability to reduce cell viability and induce apoptosis. This 
effect reached the peak at the highest tested doses. The sample PB2585 appeared to be the most 
sensible to the pro-apoptotic effect of both drugs. The fraction of apoptotic cells induced by 
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Hemidesmus 1.55 mg/mL was 36.7% vs 14.4% in the control, and by piperlongumine 14 µM was 
79.1 % vs 20.4% in the control. 
Furthermore, Hemidesmus and piperlongumine inhibited the colony formation capability of CD34+ 
leukemic cells. Only in 3 out of 6 AML samples the formation of colonies was observed in the 
control. In these patient samples, Hemidesmus 0.93 and 1.55 mg/mL induced a reduction in the 
number of CFU-GM and clusters (Fig. 35A). Moreover, after treatment with piperlongumine 14 µM 
it was not possible to observe any colony in all AML samples (Fig. 35B). In order to demonstrate 
the selectivity of action of piperlongumine and Hemidesmus toward LSC, their ability to induce 
apoptosis on CD34+ cells separated from the cord blood of healthy donors was evaluated. 
Hemidesmus did not show any increase in the apoptotic cell fraction of the CB19 sample (Fig. 33C). 
On the other hand, the pro-apoptotic potential of piperlongumine was tested on 3 cord blood 
samples. Piperlongumine, at the highest tested dose, induced a reduction of the viability associated 
with an increase in the apoptotic fraction (Fig. 34C). CB10 appeared to be the most sensible sample 
to the pro-apoptotic effect induced by piperlongumine (14 µM) with a 34.4% of apoptotic cells (vs 
2.3% of the DMSO solvent control). 
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Figure 33: Fraction of viable, apoptotic and necrotic CD34+ cells, isolated from PB and BM 
samples of AML patients (A,B) and cord blood sample from healthy donors (C), after treatment for 
24h with Hemidesmus. Patient samples are divided in two groups based on their kariotype: normal 
(A) or complex (B).  
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Figure 34: Fraction of viable, apoptotic and necrotic CD34+ cells, isolated from PB and BM 
samples of AML patients (A,B) and cord blood samples from healthy donors (C), after treatment for 
24h with piperlongumine. Patient samples are divided in two groups based on their kariotype: 
normal (A) or complex (B).  
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Figure 35: Colony-forming capability of CD34+ cells, sorted from AML patient samples, treated 
with Hemidesmus (A) or piperlongumine (B) for 24h and kept in culture for 14 days. 
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Chapter 5 
Discussion 
In this study, we show that Hemidesmus indicus, a traditionally used medicinal plant, exerts potent 
anti-leukemic effects through the modulation of different critical targets. Hemidesmus was 
subjected to an HPLC analysis to quantify its main phytomarkers, namely 2H4MBAL, 3H4MBAL 
and 2H4MBAC. 
We then examined its effect on human T-leukemia cell proliferation by focusing on cell-cycle 
regulation. According to our flow cytometry data, treatment of Jurkat cells with Hemidesmus 
resulted in a potent inhibition of cell growth, due to the block of cells in the S phase. 
Many stimuli can induce cell arrest at different phases. Agents that cause damage to DNA or 
spindle apparatus will cause either apoptosis or cell-cycle arrest, which usually occurs at the G1/S or 
G2/M boundaries
178
. Moreover, certain taxanes and vinca alkaloids that cause G2/M arrest by 
damaging microtubules have proven clinically successful for cancer treatment
179
. Consequently, 
cell-cycle arrest at the G1/S and G2/M transitions has been intensively investigated in mammalian 
cells. In contrast, relatively little is known about mechanisms that control progress within the S 
phase. S-phase arrest has been observed in mammalian cells with prolonged arrest at the G1/S 
boundary
180
; Rb(+/+) mouse embryo fibroblasts treated with cisplatin, etoposide or mitomycin
181
; 
human melanocytes treated with thymidine dinucleotides
182
; and human osteosarcoma cells 
transduced with the p21 gene
183
. 
Because our study demonstrated that Hemidesmus treatment of Jurkat cells resulted in an S-phase 
delay, we examined the changes of some regulators associated with cell cycle in order to further 
elucidate its cytostatic mechanism. The activation of preassembled replication complexes and 
initiation of DNA synthesis is mediated by cyclin A2/CDK2 complex and cyclin 
E/CDK2 complex. Cyclin A2 promotes both G1/S and G2/M transitions
184
. Cyclin A2/CDK2 
activity is first evident in late G1, persists through S phase and peaks at G2 phase until 
prometaphase
185
. Cyclin E/CDK2 activity increases in late G1 and peaks in early S phase
186
. p21 is a 
CDK inhibitor that directly inhibits the activity of CDK2 activity
187
. 
Hemidesmus treatment resulted in a significant down-modulation of CDK2, whereas the expression 
of cyclin E was increased. Although Hemidesmus caused an increase in cyclin E levels, the global 
cellular response was a block of the cell cycle. In this situation, an important role can be played by 
p21, whose over-expression results in S-phase arrest and senescence
188
. Hemidesmus did not 
modulate the expression of cyclin A2. Since cyclin A2 is mainly involved in S progression and its 
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expression peaks at G2 phase
184
, this differential regulation suggests that the effect of Hemidesmus 
resides in early S phase. 
Hemidesmus-treated cultures revealed a dose-dependent increase in the percentage of apoptotic 
cells. Apoptosis is primarily mediated through two pathways: the death receptor pathway and the 
mitochondrial pathway. In the death receptor pathway, a death receptor ligand, such as Fas ligand, 
binds to its receptor, such as Fas, triggering aggregation of the death receptor, recruitment of an 
adaptor molecule, such as FADD, as well as pro-caspase-8 or -10 forming a complex named the 
death inducing signaling complex. This results in the autocatalytic cleavage and activation of 
caspase-8 or caspase-10, leading to activation of caspase-3 or -7 and induction of apoptosis
189
. 
In the mitochondrial pathway, multidomain pro-apoptotic proteins, excessive mitochondrial calcium 
and reactive oxygen species induce the opening of the mitochondrial pore, with loss of 
mitochondrial integrity and transmembrane potential (DΨm)190. 
Cytochrome c is released from the mitochondria to form the apoptosome. The apoptosome then 
activates caspase-9, which in turn activates caspase-3, thereby inducing apoptosis. Many protein 
targets of active caspases are biologically important apoptotic indicators of morphological and 
biochemical changes associated with apoptosis
189
. One of the essential substrates cleaved by 
caspase-3 is PARP, an abundant DNA-binding enzyme that detects and signals DNA strand 
breaks
191
. In our system, Hemidesmus activated caspase-3 and induced PARP cleavage and 
cytochrome c release. The death receptor pathway was not induced by Hemidesmus, as indicated by 
the lack of activation of caspase-8. Thus, for the specific measurement of DΨm, Jurkat cells were 
loaded with the fluorochrome JC-1, a cationic probe that distributes passively between media, the 
cytosol and the mitochondria according to the Nernst’s equation, where the final distribution of the 
fluorochrome depends mainly on the transmembrane potential
192
. Compared to control cells, 
Hemidesmus-treated cells had drop in DΨm. During the effector phase of mitochondria-dependent 
apoptosis, the inner transmembrane potential of the mitochondria collapses, indicating the opening 
of mitochondrial permeability transition pores. Mitochondrial permeability transition activation 
compromises the normal integrity of the mitochondrial inner membrane resulting into uncoupled 
oxidative phosphorylation, ATP decay, mitochondrial swelling and release of apoptogenic factors. 
The structure and composition of the transition pore includes inner membrane proteins, such as 
adenine nucleotide translocator, outer membrane proteins, such as the voltage-dependent anion 
channel, and cyclophilin D at contact sites between the mitochondrial outer and inner membranes
161
 
. The inner and outer membrane proteins operate in concert to create the conductance channels
189
. 
The adenine nucleotide translocator is an ADP-ATP antiporter that imports ADP to the matrix and 
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exports ATP to the cytosol
193
. The adenine nucleotide translocator alternates between two distinct 
conformations in which adenine nucleotides are either bound to the cytosolic side (c-state) or to the 
matrix side (m-state) of the inner mitochondrial membrane
193
. CATR binds to adenine nucleotide 
translocator in the c-state. CATR binding occurs at a site similar to the ADP-binding site, thus 
preventing ADP/ATP transport. BA binds to adenine nucleotide translocator in the m-state. The two 
ligands are known to be adenine nucleotide translocator specific inhibitors
193
. The third putative 
component of the mitochondrial permeability transition is cyclophilin D, which binds to complexes 
of voltage-dependent anion channel and adenine nucleotide translocator in order to form the 
mitochondrial permeability transition complex. Cyc A was shown to block the binding of 
cyclophilin D
194
. To further elucidate the significance of mitochondria in Hemidesmus-induced 
Jurkat cell death, we investigated the effects of different inhibitors. Hemidesmus did not interact 
with adenine nucleotide translocator and did not disturb the effect of BA, CATR and Cyc A. The 
effect of Hemidesmus on mitochondrial depolarization was not even modulated by ADP. Because 
ADP is a potent ligand of the adenine nucleotide translocator
195
, the results confirm that 
Hemidesmus does not stimulate the mitochondrial permeability transition through an interaction 
with the adenine nucleotide translocator but to an unrelated mechanism. 
Numerous data have shown the pro-apoptotic effects of elevated concentrations of intracellular 
calcium
196
 and, accordingly, many calcium ionophores are also apoptotic inductors in some cell 
types
192
. Since Hemidesmus possesses a strong pro-apoptotic effect in Jurkat cells, we were 
interested in studying its calcium mobilization activity. The major pathways of [Ca
2+
]i increase are 
Ca2+ influx from extracellular space and Ca
2+
 release from internal Ca
2+
 stores. Numerous studies 
have demonstrated that both pathways appear to be involved in the [Ca
2+
]i increase associated with 
apoptosis
197
. Our study demonstrated that Hemidesmus induced [Ca
2+
]i rise and explored the 
underlying mechanisms. Removal of extracellular Ca
2+
 did not abolish the [Ca
2+
]i raise induced by 
Hemidesmus. Moreover, our results suggest that Hemidesmus did not cause Ca
2+
 influx via 
stimulating store operated Ca
2+
 entry or voltage-gated Ca
2+
 channels because nifedipine (a blocker 
of L-type voltage-gated Ca
2+
 channels)
198
 and econazole (an inhibitor of store-operated Ca2+ 
channels)
199
 failed to inhibit the [Ca
2+
]i raise. Aristolochic acid, a phospholipase A2 inhibitor, 
increased Hemidesmus-induced [Ca
2+
]i raise. These findings indicate that phospholipase A2 could 
be not required for Hemidesmus-induced Ca
2+
 signal in our experimental model. However, 
aristolochic acid is able to induce a rapid rise in [Ca
2+
]i through both release of endoplasmic 
reticulum stores and influx of extracellular Ca
2+
 
200
. To better understand the mechanism of 
Hemidesmus, we used thapsigargin, a compound that induces the release of intracellular 
endoplasmic reticulum Ca
2+
 stores and prevents refilling by inhibition of the endoplasmic reticulum 
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Ca
2+
-ATPase
201
. Thapsigargin significantly increased Hemidesmus-induced [Ca
2+
]i raise. On the 
whole, our results suggest that Hemidesmus may cause [Ca
2+
]i raise through the mobilization of 
intracellular Ca
2+
 stores. 
Moreover, the intrinsic pathway is strongly regulated by interactions between members of the Bcl-2 
family. This family of proteins is composed of three groups defined according to their function and 
content of Bcl-2 homology (BH) domains. Bcl-2, the oncoprotein activated by chromosome 
translocation in follicular lymphoma
202
, inhibits apoptosis
203
, as do four of its homologues Bcl-XL, 
Bcl-w, Mcl-1 and A1, which share four BH domains. Within the Bcl-2 family, there are also pro-
apoptotic effectors like Bax and Bak that share three BH domains, as well as a C-terminal 
transmembrane segment that selectively targets these proteins to the membranes of mitochondria 
and endoplasmic reticulum. Lastly, a large and diverse pro-apoptotic group within this family, 
named BH3-only proteins, contains only a single BH3 domain, such as Bim, Puma, Bid, and Noxa. 
Induction of apoptosis requires the activation of members of both of these death-promoting 
families
204, 205
. The induction of BH3-only proteins results in the neutralization of pro-survival 
proteins, and in the subsequent activation of Bax and Bak. The activation of the two pro-apoptotic 
effectors involves their conformational change and homo-oligomerisation on the mitochondrial 
outer membrane, which leads to its permeabilization. It has been shown that the Bcl-2 protein 
physically interacts with several of its homologous proteins. The most important interactions are 
considered to lie in Bcl-2/Bax dimerization. Thus, we studied the profile of Bcl-2 and Bax gene 
products in terms of protein and gene expressions. Our results showed that Bax protein expression 
was markedly induced, suggesting that Bax was up-regulated and played an important role in the 
induction of apoptosis after Hemidesmus exposure. However, in contrast to the Bcl-2 inhibiting 
apoptotic cell death, the present study found that Bcl-2 expression was also increased after 
Hemidesmus exposure compared to control. The increase in anti-apoptotic Bcl-2 protein may serve 
as a compensatory protection of the leukemia cells upon Hemidesmus insult. Although the 
expressions of Bcl-2 and Bax, both of them, were increased, the ratio of Bax/Bcl-2 (pro- to anti-
apoptotic proteins) was also increased after Hemidesmus treatment. The findings support the notion 
that the relative concentrations of pro-apoptotic and anti-apoptotic proteins may act as a rheostat for 
the cell death program
206
. Notably, the mRNA expression of BCL2 and BAX was reduced by 
Hemidesmus treatment. This result was in conflict to what demonstrated at post-transcriptional level 
with the overexpression of the two Bcl-2 family proteins. Since both proteins are degraded through 
an ubiquitin-proteasome dependent pathway, we studied the ability of Hemidesmus to modulate this 
pathway. The 26S proteasome is critical for the maintenance of homeostasis of most intracellular 
proteins
207
. A large number of proteins involved in cell cycle progression and apoptosis are 
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regulated by ubiquitinylation and proteasome-mediated degradation. Therefore, targeting 
proteasome pathway has emerged as a promising approach to cancer therapy
208
. Bortezomib, a cell-
permeable dipeptidyl boronic acid, is a specific and selective inhibitor of 26S proteasome and was 
the first proteasome inhibitor used for the treatment of relapsed or refractory multiple myeloma
209
. 
In our experimental model, Hemidesmus reduced the 26S proteasome expression. Its ability was 
comparable with that expressed by bortezomib 10 µM and MG132 0.5 µM. Furthermore, 
Hemidesmus induced a post-transcriptional down-regulation of the proteasome mRNA. These 
results partially justify the differential post-transcriptional and post-translational regulation of Bax 
and Bcl-2 evoked by Hemidesmus. 
Among the pro-survival Bcl-2 family members, Mcl-1 is essential for the survival of multiple cell 
lineages in the adult, including lymphocytes
210, 211
, HSCs
212
, neutrophils
213, 214
, neurons
215
, and for 
embryonic development
216
. Moreover, Mcl-1 is frequently over-expressed in human cancers
217
 
representing a key factor in the resistance of leukemia to conventional anti-cancer therapy
218
. Mcl-1 
is localized to distinct mitochondrial sub-compartments, with differential functions that affect 
mitochondrial activity and integrity. On the outer mitochondrial membrane, Mcl-1 exerts its anti-
apoptotic activity where it antagonizes Bax and Bak activation, maintaining mitochondrial integrity, 
and inhibits mitochondrial calcium signals following an apoptotic stimulus
219
. In contrast, Mcl-1 
localized in the mitochondrial matrix is unable to inhibit apoptosis, but maintains normal inner 
mitochondrial membrane structure, regulates fusion and promotes the assembly of ATP synthase 
oligomers; thereby, it facilitates mitochondrial homeostasis and supports mitochondrial bioenergetic 
function
220
. A down-regulation of Mcl-1 is often sufficient to promote apoptosis in leukemic cells, 
suggesting that Mcl-1 can be a potential therapeutic target in the treatment of several human 
leukemias
218, 221-223
. To date, numerous strategies, including small molecule BH3 mimetics, stapled 
BH3 peptides, and down-regulation of Mcl-1 by kinase inhibitors, deubiquitinase inhibitors, and 
antisense oligonucleotides, have been attempted to target Mcl- 1 for cancer treatment
224
. However, 
none of the Mcl-1 specific inhibitors are in clinic. Our study revealed that Hemidesmus induces a 
rapid decrease in Mcl-1 protein levels. This regulation appeared to be essentially post-translational 
because Mcl-1 mRNA was up-regulated at all treatment times. The increased gene expression of 
Mcl-1 may represent as a mechanism of leukemic cells protection against the degradation of the 
anti-apoptotic protein induced by Hemidesmus. At post-translational level, Mcl-1 can be cleaved by 
caspases, specifically caspase-3, at Asp127 and Asp157. This results in the removal of a large part 
of the N-terminus of Mcl-1, leaving the BH1-3 and the C-terminal transmembrane domain intact. 
The caspase-dependent cleavage of Mcl-1 suggests that the cleavage products become pro-death 
apoptosis
225-228
. Since Hemidesmus stimulate caspase-3 activity, its induction may be responsible 
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for the post-translational down-regulation of Mcl-1. Furthermore, Mcl-1 is subject to a rapid 
turnover through ubiquitin-dependent protein degradation by the 26S proteasome. One of E3 ligases 
of the proteasome, MULE/LASU1, is a BH3-only Hect E3-ligase whose BH3 domain interacts with 
the hydrophobic BH3 binding pocket of Mcl-1, and not with other pro-survival Bcl-2 family 
members
229, 230
. Noxa has been shown to associate mainly with Mcl-1, and induce ubiquitin-
proteasome-mediated degradation of Mcl-1
231
. In our study, despite the clear post-transcriptional 
stimulation of Noxa induced by Hemidesmus, the protein levels were not modulated, even if the 
proteasome inhibition ability exerted by Hemidesmus should have led to an accumulation of the 
BH3-only family protein
232
. Reasonable explanations for this phenomenon could be the lack of a 
specific antibody able to recognize the epitope of Noxa in dimmer with Mcl-1
233
, or the high 
physiological level of Noxa in Jurkat cells that could make the detection of alterations in protein 
expression difficult
234
. The importance of the Noxa/Mcl-1 balance has been recently proved to play 
an important role in the intrinsic apoptotic pathway
234, 235
. Treatments with Hemidesmus caused a 
variation in the Noxa/Mcl-1 ratio in favor of Noxa. These results showed how much the down-
regulation of Mcl-1 and its close relation with Noxa are crucial for the pro-apoptotic activity 
exerted by Hemidesmus. 
Senescence is an established cellular pathway involved in all aspects of cancer biology from 
carcinogenesis to tumor proliferation and appears to be a major obstacle for cancer progression
236
. 
Senescence appears to be controlled by distinct pathways, but in general it is initiated by tumor 
suppressors like p53. Thus, without the loss of tumor suppressor genes like p53, cells expressing or 
even over-expressing oncosuppressors fail to become cancerous due to senescence
237
. Bolesta et al. 
showed that Mcl-1 plays an important role in preventing chemotherapy-induced senescence in both 
a p53-dependent and -independent manner and that Mcl-1-mediated inhibition can enhance tumor 
growth in vivo. Moreover, they observed an increased p21 expression in all cases where senescence 
can be induced
238
. This allows to speculate that Mcl-1 down-regulation represents a key step not 
only in the induction of apoptosis but also in the inhibition of the cell cycle progression induced by 
Hemidesmus. This result was supported by the fact that Hemidesmus did not show any modulation 
of p53 in our experimental setting. 
Other key factors in the regulation of cellular apoptosis pathway, in both physiological and 
pathological conditions, are ROS. The level of ROS influences several proteins involved in the 
apoptotic and cell-cycle regulation. Mitochondria are strictly correlated with ROS as their source 
and target. As an example, the release of cytochrome c and then the activation of caspases are 
directly and indirectly regulated by ROS
239
. Furthermore, several studies reported that p21 
expression during senescence is dependent on the production of ROS
240, 241
. Hemidesmus showed 
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the ability to increase the production of ROS starting after short-term treatments. The association 
with NAC resulted in a significant reduction of the pro-apoptotic capability of Hemidesmus. 
Altogether, our results suggest that the growth inhibition of Jurkat cells produced by Hemidesmus 
results from a combination of apoptosis and of cell-cycle derangements in which S accumulation, 
p21 increase, down-regulation of Mcl-1, and induction of ROS are key events. 
The Hemidesmus-induced S accumulation could have potentially important clinical implications. 
This factor made evaluation of the pro-apoptotic effects of Hemidesmus together with anticancer 
agents an important focus of our pre-clinical experiments. Cells which are synthesizing DNA 
usually display increased susceptibility to most anticancer drugs (e.g. antimetabolites or 
intercalating agents)
242
. The anticancer agents tested in this study in association with Hemidesmus 
included 6-thioguanine, cytarabine and methotrexate. Their inclusion was important for determining 
whether Hemidesmus can enhance the anticancer efficacy of chemotherapeutic agents. Accordingly, 
the ability of Hemidesmus to increase the fraction of cells engaged in the S-phase of the cell-cycle 
was useful in potentiating the efficacy of 6-thioguanine, cytarabine and methotrexate. 
The research continued with the study of the pro-differentiating ability of Hemidesmus. The 
stimulation of differentiation is a recognized alternative in the treatment of cancer, by generating 
cells with limited or no replicative capability able to enter in the apoptotic pathways
243
. It is well 
known that the only successful differentiation therapy in the clinic still remains treatment with all-
trans retinoic acid plus arsenic trioxide
244
. At molecular level, all-trans retinoic acid and arsenic 
trioxide are able to modulate synergistically multiple downstream pathways/cascades. This 
combination therapy, compared to the traditional anthracycline-based regimen, results in lower 
toxicity, improvement of long-term outcome, higher survival rates, with >90% patients disease-free 
after 5 years by the end of treatment
244, 245
. 
The ability of Hemidesmus to induce cytodifferentiation was screened on HL-60 cells that have the 
potential to differentiate into macrophages or granulocytes
246
. Treatment of HL-60 cultures with 
Hemidesmus caused apoptosis and cell-cycle inhibition, which may represent an event only partly 
dependent on cytodifferentiation in our experimental conditions. In fact, the induction of apoptosis 
and the inhibition of cell-cycle were almost simultaneous. The early appearance of cell-cycle-
inhibition and apoptosis compared with cytodifferentiation clearly indicates that cytotoxicity and 
cytostasis events are primary direct effects due to Hemidesmus and are not due to activation of 
apoptosis and/or inhibition of cell proliferation as a consequence of cell’s differentiation. Although 
reported in vitro, those effects are worthy of comparing with the effects recorded for all-trans 
retinoic acid on the same cell line. No induction of apoptosis was observed on HL-60 cells after 48h 
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of treatment with all-trans retinoic acid. By 72h, a modest fraction of cells incubated with all-trans 
retinoic acid became apoptotic
247
. These results are consistent with the evidence that apoptosis 
induced by all-trans retinoic acid is a consequence of its cytodifferentiative potential
248
 and does not 
represent an independent event. The treatment of HL-60 with Hemidesmus altered cell-cycle 
progression though the induction of a dose- and time-dependent accumulation of cells in the G0/G1 
phase evident after 24h of treatment. This is a critical point because cells need to exit from cell 
cycle before differentiating and this decision is commonly made in G1 phase
249
. By comparing our 
results with those obtained with all-trans retinoic acid and arsenic trioxide on the same cell line, we 
observe that the antiproliferative effects of Hemidesmus are much earlier than those of all-trans 
retinoic acid and arsenic trioxide, evident after 4 and 5 days of incubation, respectively
250
. 
Our biological data support the conclusion that Hemidesmus significantly induced HL-60 to 
differentiate along the macrophage and granulocyte lineage. The subsequent morphological analysis 
by TEM confirmed the cytodifferentiation ability of this traditional plant. The ability of 
Hemidesmus to induce differentiation into granulocytes resulted in a less extent compared to the 
data concerning the differentiation induced by all-trans retinoic acid, but in a greater extent 
compared to arsenic trioxide
250
. 
Taken together, these results evidence the ability of Hemidesmus to induce a plethora of effects, all 
contributing to its anti-leukemic effect. This aspect appears important because the therapeutic 
success of drugs used in the acute promyelocytic leukemia results from the balance of self renewal, 
apoptosis and differentiation. Indeed, in clinical practice, retinoic acid by itself only rarely yields 
prolonged remission, even thought it induce massive differentiation. Otherwise, in vivo studies on 
arsenic trioxide reported an initial induction of apoptosis followed by slow blast differentiation
245
. 
The study continued investigating the ability of Hemidesmus to modulate new blood vessels 
formation. Angiogenesis plays a crucial role in the development and spread of tumor
251
. Cancer 
cells are not able to grow in diameter more than 1-2 mm
3
 and metastasis without blood circulation. 
To spread, they need to be supplied by blood vessels that bring oxygen and nutrients and remove 
metabolic wastes. In absence of vascular support, tumors may become necrotic or even apoptotic
252
. 
Angiogenesis has been identified as a hallmark of tumor progression
253
 and therefore anti-
angiogenic therapy has become a new promising anticancer strategy. Nowadays, numerous anti-
angiogenic therapeutics are used alone in maintenance treatment
254
 or in polytherapy regimens 
against cancer
255
. 
Hypoxia has a strong influence in the biology of tumors and in their response to treatments. In 
particular, hypoxia plays a central role in the induction of angiogenesis. Limitation of oxygen 
diffusion in vascular primary tumor arise hypoxic conditions and stimulates the formation of tumor 
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abnormal microvasculature
256
. The master regulator of cellular adaptation in response to oxygen 
deprivation is HIF. HIF is a heterodimer and its subunit HIF-1α is involved in the initiation of a 
transcriptional program that promotes an aggressive tumor phenotype leading to metastasis and 
tissue invasion
257
. The hypoxic condition enhances the transcription of VEGF, by HIF-1α. Among 
the few growth factors that regulate angiogenesis, VEGF has a pivotal role. An increased activity of 
VEGF has been reported in the most aggressive cancers
258
 and it is related with a poor prognosis
259
, 
also in hematological malignancies
260
. 
For several years angiogenesis has been correctly attributed only to solid tumor. Nonetheless, 
several in vitro
261, 262
, in vivo
263, 264
, and clinical studies
265, 266
 strongly suggest that induction of 
angiogenesis in hematological tumors has a pathophysiological relevance for disease progression 
and represents a valid pharmacological target. As an example, Kopp et al. showed how the BM 
vasculature plays an important role in hematopoiesis in health and disease. Kopp demonstrated the 
role of mural cells (pericytes and smooth muscle cells) in providing a specialized vascular “niche” 
for HSCs
267
. Therefore, development of pharmacological strategies that target both the stromal and 
tumor compartments, such as the combination between the traditional cytotoxic chemotherapy and 
anti-angiogenic agents, may conduce to an improvement of cancer treatment.  
In this context, Hemidesmus represents an interesting strategy due to its capability to contemporary 
modulate several targets. We have already demonstrated its ability to induce apoptosis, interfere 
with cell-cycle progression and induce differentiation in leukemic cell lines. An in vitro model of 
angiogenesis was used and it focused on endothelial cell proliferation, formation of capillary-like 
structures in matrigel, quantification of the sprouting, migration, and invasion
268
. Treatment with 
Hemidesmus inhibited angiogenesis in normoxia and hypoxia through the regulation of key factors 
of the neovascularization process. Endothelial cell proliferation is strictly correlated with the 
angiogenic and metastatic process
269
. In both O2 conditions, Hemidesmus reduced proliferation 
without showing any appreciable effect in the induction of apoptosis on HUVECs. Using the in 
vitro angiogenesis assay, we found that Hemidesmus was able to inhibit microvessels outgrowth in 
a dose-dependent manner, also in association with VEGF, a well-know angiogenesis inducer. The 
expression levels of the principal proteins involved in the regulation of angiogenesis (HIF-1α, 
VEGF and VEGFR-2) and their mRNAs have been analyzed after treatment with Hemidesmus. A 
down-regulation of HIF-1α protein level was reported after treating HUVECs in hypoxic condition, 
while in normoxia no modulation was reported. At gene level, Hemidesmus induced a dose-
dependent reduction in the expression of HIF-1α, both in normoxic and hypoxic conditions, but the 
major down-regulation was observed in the low oxygen condition. This result is partially justified 
by the fact that the hypoxic microenvironment stimulates tumor angiogenesis more than in normal 
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O2 pressure condition
270
. Moreover, the down-regulation of HIF-1α induced by Hemidesmus 
demonstrates its ability to overcome the accumulation of the protein that typically appears in 
hypoxic condition due to the inhibition of its degradation
271
. Additionally, Hemidesmus down-
regulated the VEGF protein expression in both O2 conditions. This result clearly demonstrates the 
role of HIF-1α in the modulation of VEGF in hypoxic conditions. Between the two VEGF 
receptors, VEGFR-2 appears to be the major transducer of VEGF signals in endothelial cells, 
leading to cell proliferation, migration, differentiation, capillary-like formation and vascular 
permeability. In the light of these considerations, inhibition of VEGFR-2 might represent an 
interesting approach for an anti-angiogenic intervention
272
. The protein expression of VEGFR-2 
was reduced by Hemidesmus only in condition of low oxygen, while, a modulation of the gene 
appeared in both O2 conditions. Taken together our results suggest that the inhibition of 
angiogenesis induced by Hemidesmus is mediated through two distinct mechanisms according to 
the oxygen availability. In normoxic condition, the reduced expression of VEGF induced by the 
decoction seems to be the main cause for the inhibition of angiogenesis, while the inhibition of 
angiogenesis induced by Hemidesmus in hypoxic condition is regulated by a more complex 
mechanism, which involves the inhibition of HIF-1α first, VEGF and its receptor VEGFR-2. 
Neovascularization influences the dissemination of cancer cells throughout the entire body 
eventually leading to metastasis formation. The vascularization level of a solid tumor is thought to 
be an excellent indicator of its metastatic potential
273
. In this context, Hemidesmus suppressed 
significantly invasion and migration of endothelial cells. These results demonstrate that 
Hemidesmus indicus modulates angiogenesis by the inhibition of new vessel formation and 
migration/invasion. Indeed, it down-regulates key proteins and genes involved in neoangiogenesis, 
such as HIF-1α, VEGF, and VEGFR-2. Based on these data, the use of Hemidesmus might be 
promoted as a therapeutic agent for diseases in which the inhibition of angiogenesis could be 
beneficial, in particular in anticancer therapy. 
In the final part of this study we explored the ability of Hemidesmus to induce apoptosis in fresh 
AML cells. Ex vivo samples represent a good surrogate for determining patient’s cellular response 
to treatment and predicting clinical outcome. This can not be realized by using cell lines, which 
markedly differ from blasts in terms of growth kinetics and pharmacological determinants
35, 274-276
. 
We observed that Hemidesmus was a potent inducer of apoptosis in AML cells. Its pro-apoptotic 
activity was particularly marked on blasts obtained from a recidivant patient (AML4), characterized 
by a genomic alteration of the FLT3 gene, including FLT3/ITD. This observation is particularly 
interesting because FLT3/ITDs are predictive of relapse and poor outcome in the chemotherapy 
setting
277
.  
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The characterization of stem cells in different leukemic processes led to the conclusion that these 
cells can actively contribute to the failure of therapies focalized on the eradication of leukemic 
blasts. CSCs are naturally resistant to chemotherapy through their quiescence, their ability for DNA 
repair, and ABC transporter expression. As a result, LSCs that survive from traditional anti-
leukemic chemotherapy can support the regrowth and the relapse of leukemia
7
. Moreover, LSCs 
play a pivotal role in the process of leukemia initiation and progression. For these reasons, LSCs 
represent a potential and promising pharmacological target for the treatment of leukemia
278
.  
We investigated the effect of Hemidesmus and piperlongumine on CD34+ sorted subpopulation 
from 6 primary human AML and healthy cord blood samples. Both drugs induced apoptosis and 
inhibited the colony formation in CD34+ AML patient samples, regardless of their karyotype. This 
evidence is extremely important since complex karyotype AML is strongly associated with poor 
prognosis
279
. The effect of piperlongumine in the inhibition of colony formation resulted more 
pronounced at the highest tested concentration and brought to a complete lack of colonies. Of note, 
Hemidesmus did not show any effect on healthy CD34+ cells at all tested concentrations, while 
piperlongumine induced a low induction of apoptosis at the concentration 14 µM. Since LSCs plays 
key role in the initiation and development of leukemia, the selectivity of action toward them 
expressed by both Hemidesmus and piperlongumine outlines their interesting pharmacological 
profile in the treatment of leukemia. 
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Chapter 6  
Conclusions 
 
On the whole, our results indicate that the traditional preparation of Hemidesmus indicus could be a 
promising botanical drug in the oncologic area. The simultaneous modulation of several key 
processes in cancer development like apoptosis, ROS formation, cytodifferentiation and 
angiogenesis makes Hemidesmus indicus a promising botanical drug in the treatment of leukemia. 
Furthermore, Hemidesmus showed a selective action toward LSCs that are viewed as the origin of 
the hierarchy of tumor cells. Since selective targeting and low toxicity for normal host tissues are 
fundamental requisites for anticancer drugs, it is also interesting to note that the cytotoxic activity of 
Hemidesmus on nontransformed cells was significantly lower than that observed in cancer cells 
(data not shown) and absent on healthy CD34+ cells. This could allow the definition of a range of 
concentrations potentially active only on cancer cells. 
Hemidesmus contains a mixture of known and possibly active compounds and this aspect poses 
many challenging issues. However, it is a relatively simple botanical product (single part of single 
plant). As a naturally occurring mixture from a single part of a single plant, it is not considered a 
combination product
115
. Of note, FDA demonstrated that therapeutic consistency of the commercial 
batches of simple botanical preparations (single part of single plant) can be assured. Although the 
chemical constituents of a botanical drug are not always well defined and in many cases the active 
constituent is not identified nor is its biological activity characterized
116
, variations in raw material 
quality can be minimized by restricting the cultivars, the composition of the preparation can be 
equivalent by robust chemistry, manufacturing and control measures, ‘fingerprinting’, and 
conducting chromatographic analyses of marker compounds
115
. Our HPLC phytochemical analysis 
of Hemidesmus indicus demonstrated the presence of 2H4MBAC, 2H4MBAL and 3H4MBAL, 
which can be used as fingerprint. Of note in this context, the phytochemical analysis performed on 
different batches of Hemidesmus demonstrated that the levels of the above reported phytomarkers 
were not statistically different among batches. The above reported phytomarkers lacked pro-
apoptotic activities, while their association induced apoptosis in Jurkat cells. Although relatively 
high doses of single bioactive agents may show potent anticarcinogenic effects, the antitumor 
properties of interactions among various ingredients that potentiate the activities of any single 
constituent may better explain the observed pharmacological effect of whole plant, as evidenced for 
other plants in many in vitro and in vivo studies
170, 280, 281
. On these bases, we conclude that 
Hemidesmus can represent a valuable strategy in the anticancer pharmacology, and should be 
considered for further investigations. 
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As regards piperlongumine, many studies reported its ability to eradicate cancer cells. Through our 
study we expanded the knowledge about this promising natural agent by the demonstration of its 
selective action toward LSCs. Through its anti-leukemic effects that include induction of apoptosis, 
cell-cycle arrest, ROS induction, inhibition of angiogenesis/metastasis and LSCs elimination, 
piperlongumine represents an example of multi-target drug and could lead to treatment and long-
term remission of cancer.  
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